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Cancer patients often experience cachexia, a form of weight loss consisting mostly 
of skeletal muscle wasting. Muscle wasting leads to physical disability, poor quality of 
life, reduced tolerance to treatments and shorter survival. Although the causes of cancer-
related muscle atrophy have been studied for decades, the exact mechanisms through 
which cancer and its treatments promote muscle wasting have yet to be defined.  
The overall aim of this dissertation is to examine the mediators of muscle wasting 
in cancer patients during their treatment and examine the modulatory role of exercise to 
maintain muscle size and function. To address these aims, we studied two different 
populations of cancer patients to examine the effects of tumor-related factors and 
chemotherapy to cause muscle atrophy using an in vitro skeletal muscle system. 
We examined whether tumor cells secrete factors to promote atrophy by evaluating 
the effects of tumor-conditioned media (CM) from murine and human lung tumor cells 
(hTCM) on cultured muscle myotubes. We hypothesized that conditioned media from 
murine and human tumor cells would reduce myotube myosin content a marker for 
atrophy, decrease mitochondrial content, and increase mitochondrial reactive oxygen 
species production (ROS), all of which have been reported in model systems using murine 
tumor cell CM. 
Cancer patients frequently receive chemotherapy, some of which are known to be 
myotoxic. Whether these drugs promote muscle wasting, however, is not clear. To address 
this question, we assessed skeletal muscle structure and protein expression in 13 women 
diagnosed with breast cancer, who were receiving adjuvant chemotherapy following 
tumor resection, and 12 non-diseased controls. Furthermore, we evaluated the role of 
individual chemotherapeutics (doxorubicin and paclitaxel) to cause atrophy, 
mitochondrial loss and increased reactive oxygen species production in C2C12 cultured 
muscle myotubes, as well as the modifying effects of a mitochondrial-targeted anti-
oxidant.  
Pre-clinical models show that exercise protects against the deleterious effects of 
chemotherapy, although the mechanisms underlying these effects are not known. To 
address this question, we utilized an in vitro model of exercise by treating C2C12 
myotubes with doxorubicin (DOX; 0.2 μM for 3 days) with or without daily bouts of 
electrical field stimulation (STIM). 
Our results advance the field by showing that the treatments, and not tumor-
related factors, promote skeletal muscle atrophy. Moreover, exercise is effective at 
countering the deleterious effects of chemotherapy and acts via mechanotransductive 
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Cancer-related muscle wasting is a multifactorial condition that negatively affects 
patients’ prognosis and quality of life (84, 113, 164). Traditionally, cachexia has been 
defined by a specified percentage of weight loss over time (i.e., 5% weight loss in the 
preceding 6-12 months). However, the assessment of weight loss alone does not reflect 
the complete scope of pathophysiologic changes or the clinical impact. The severity and 
phenotypic presentation of cancer-related atrophy may vary, and often muscle wasting 
may not be diagnosed (5, 42). Regardless, skeletal muscle loss is considered a meaningful 
prognostic factor during cancer (7) and has been associated with higher incidence of 
therapy toxicity, increased morbidity, and mortality (129, 156).  
The pathogenesis and molecular mechanisms underlying cancer-related muscle 
wasting have not been fully elucidated. Available evidence suggests an imbalance 
between the rate of synthesis and protein degradation, although impaired defective 
myogenesis may contribute as well. In addition, alterations in energy metabolism 




Skeletal muscle structure and function 
Skeletal muscle fibers (muscle cells) are composed of intracellular contractile 
proteins called the myofilaments. These myofilaments are made up of bundles of thick 
and thin filaments that form myofibrils; bundles of myofibrils form muscle fibers; and 
finally, bundles of muscle fibers are skeletal muscle tissue. The thick myofilaments 
contain myosin protein and thin myofilaments contain actin protein (Figure 1). The thin 
and thick filaments, respectively, provide contractility to the cell and are spatially 
arranged in regular and repetitive structures called the sarcomeres. The interaction of 
these two myofibrillar proteins allows muscles to contract, and the mechanics of 
contracture can be classified into fiber types based on different myosin structures 
(isoforms) or physiologic capabilities (152). The three myosin isoforms that were 
originally identified in humans were MHCI, MHCIIa, and MHCIIx/d, and they 
corresponded to the isoforms identified by myosin ATPase staining as types I, IIA, and 
IIX, respectively (125). In older literature what was originally identified in humans as 
MHCIIb is actually MHCIIx/d, as humans do not express a fourth and fastest myosin 
heavy chain isoform (MHCIIb) (65). Although rare, a fiber can have both the MHC I and 
the MHC IIa isoform and is classified as a hybrid type I/IIa fiber. Similarly, some may 
have MHC IIa and MHC IIx isoforms termed a hybrid type IIa/IIx fiber. (Table 1) 
summarizes the properties of the three muscle fiber types found in human skeletal 
muscle. 
Muscle contracture occurs by a process called excitation contracture coupling (EC 
Coupling), when the release of acetylcholine from the axon ending into the synaptic cleft 
at the neuromuscular junction, initiates the depolarization of sarcolemma (muscle fiber 
  
4  
membrane), and leads to release of Ca2+ ions from the sarcoplasmic reticulum into the 
sarcoplasm (cytoplasm). Ca2+ binds the troponin proteins found on the thin myofilaments, 
initiating the attachment of actin to the binding site of myosin allowing the muscle 
contraction process to occur, generating force. There are various molecular signals that 




Pathways regulating skeletal muscle mass 
Muscle atrophy involves the shrinkage of myofibers (decreased muscle fiber cross-
sectional area (mCSA)) due to a net loss of proteins partly related to upregulation of 
degradation pathways, such as the ubiquitin-proteasome system. Recent studies have 
shown these catabolic pathways modulate one another at different levels, and are coupled 
to anabolic pathways. The result is a balance between protein breakdown and synthesis 
that reflects the physiological state of the muscle fiber.  
1.1.1 Protein breakdown 
Muscle atrophy occurs with a change in the normal balance between protein 
synthesis and protein degradation. The particular protein degradation pathway, which 
seems to be responsible for much of the muscle loss seen in atrophy, is the ATP-
dependent ubiquitin-proteasome pathway. In muscle, the ubiquitin-proteasome system is 
required to remove sarcomeric proteins in response to changes in muscle health (13, 26). 
Skeletal muscle-specific ubiquitin E3 ligases Muscle RING finger 1 (MuRF1) and 
muscle atrophy F-box (MAFbx)/atrogin-1 have been studied widely and play an essential 
role during skeletal muscle atrophy (47, 105). This link is further supported by animal 
studies in mice lacking atrogin-1/MAFbx and MuRF1 (15) that show both are needed for 
atrophy, with other more recent studies showing MuRF1 not atrogin-1 knockout mice to 
be resistant to dexamethasone-induced muscle atrophy (6). Additionally, MuRF1 has 
been reported to interact with and control the half-life of important muscle structural 
proteins such as myosin (25, 26, 43), suggesting that MuRF1 plays a dominant role in 
various skeletal muscle atrophy conditions. It has also been reported that upregulation of 
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these proteins is time-dependent, with no changes in MuRF1 expression seen with a 
prolonged catabolic stimulus (119). Forkhead box class O family member proteins 
(FoxOs) are transcription factors that play important roles in regulating the expression of 
genes involved in cell growth. Four FoxO members in humans, FoxO1, FoxO3, FoxO4, 
and FoxO6, are all expressed in skeletal muscle, but FoxO1, FoxO3 members are the 
most studied in muscle. FoxO1 and FoxO3 are key factors of muscle protein breakdown, 
as the major transcription factors regulating both the MuRF1 and MAFbx expressions 
(142, 153), with FoxO3a implicated as a major regulator in several disease states (1, 120, 
182, 183). FoxO/MuRF1 signaling proteins are regulated on several fronts. In skeletal 
muscle, the most studied post-translational modification of FoxOs is phosphorylation. 5' 
adenosine monophosphate-activated protein kinase (AMPK) and Protein kinase B (PKB), 
also known as (Akt) have opposite effects on FoxO3 localization and activity.  
AMPK plays a role in cellular energy homeostasis when cellular energy is low it 
phosphorylates FoxO3 at two regulatory sites (Ser-413/588) in skeletal muscle, leading to 
its activation under stress conditions (115, 118, 140). Moreover, AMPK activation is 
associated with increasing levels of FoxO1 and FoxO3 mRNAs and protein content 
(118).  
Akt is a serine/threonine protein kinase that plays a key role in insulin and 
PI3K/Akt/mTOR signaling pathways, contributing to the regulation of energy 
metabolism and protein synthesis. An essential regulator of FoxO activity, it inhibits 
FoxO1, 3 and 4 by phosphorylation (Ser-253/315, Thr 32) under mitogenic activation 
  
7  
(153) (Figure 2), preventing up-regulation of numerous ubiquitin–proteasome and 
autophagy-related genes in muscle. 
Another regulator of skeletal muscle atrophy is nuclear factor-kappaB (NF-κB), 
which is a major regulator of gene transcription in response to oxidative, energetic, and 
mechanical stress in skeletal muscle. Chronic activation of this signaling pathway has 
been implicated in the development of various pathologies, such as cancer-related muscle 
wasting. NF-κB transcription factors, which are expressed in skeletal muscle, mediate the 
effect of inflammatory cytokines, particularly tumor necrosis factor-α (TNFα), on muscle 
wasting (124). TNFα is thought to act via Mitogen-activated protein kinases (MAPKs) to 
stimulate expression of the ubiquitin ligase atrogin1/MAFbx and MuRF1in skeletal 
muscle (71, 89). Indeed, muscle-specific overexpression of NF-κB regulators in mice has 
led to severe muscle wasting mediated, at least in part, by MuRF1activity (16, 101).  
Other degradation pathways in skeletal muscle include the Ca2+-dependent 
proteases, lysosomal system, and caspases, these pathways will not be covered in this 
review. However, Akt regulates both the ubiquitin-proteasome system and the autophagy-
lysosome pathway, and this action is mediated by FoxO transcription factors.  
 
1.1.2 Protein synthesis 
The growth of skeletal muscle mass, like the mass of any other tissue, depends on 
protein turnover and cell turnover (143). Cellular turnover plays a major role during 
muscle development in the embryo. Moreover, satellite cell incorporation into the 
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growing fibers takes place during postnatal muscle growth (110) simultaneously with 
increased protein synthesis. However, the contribution of cellular turnover in adult fibers 
is minor, and its role in hypertrophy has been recently debated (80, 96). In adult muscle, 
the physiological conditions promoting muscle growth are mainly related to increasing 
protein synthesis and decreasing protein degradation. However, satellite cells are 
activated in compensatory hypertrophy (80, 110), and the addition of new nuclei to the 
growing fiber seems to be required for extreme hypertrophy and therefore cannot be 
completely discounted as a contributing mechanism. The pathways controlling cellular 
and protein turnover are different, and their contribution to muscle hypertrophy has to be 
considered.  
Under normal physiological condition, the IGF-1-Akt-mTOR pathway is a key 
regulator of protein synthesis in skeletal muscle (59, 145) with downstream of Akt that 
include glycogen synthase kinase 3, the mammalian target of rapamycin (mTOR), 
p70S6K, and PHAS-1 (4EBP-1), all key regulatory proteins involved in translation and 
protein synthesis  (56, 135). Changes in the Akt/mTOR and Akt/GSK3 pathways induced 
skeletal myotube hypertrophy (135). Indeed, genetic models that overexpress or code 
constitutively active forms Akt induced muscle fiber hypertrophy both in vivo (122) and 
in vitro (83, 136). Knockout models of Akt display growth defects (133), and those in 




1.1.3 Skeletal muscle mitochondrial homeostasis  
Several metabolic adaptations occur in atrophying muscles. In many forms of 
muscle wasting, expression of a variety of enzymes important for oxidative 
phosphorylation is suppressed (29). Dysfunctional mitochondria, in particular, are 
thought to play a key role in muscle function decline, as the mitochondria are the main 
producers of both cellular energy and free radicals. Mitochondrial dysfunction has been 
tightly associated with excess production of reactive oxygen species (ROS) (97). 
Chronically elevated ROS can initiate DNA damage, protein oxidation, increased 
oxidative damage and reduced oxidative capacity. These biochemical changes are 
accompanied by changes in skeletal muscle dynamics, such as a decrease in 
mitochondrial biogenesis and an increase in autophagy/mitophagy (Figure 3). 
Mitochondria are dynamic, existing in networks that are constantly being remodeled by 
biogenesis, fusion and fission, and degradative processes. 
Recent studies have shown that PGC-1α, the master regulatory gene for 
mitochondrial biogenesis, is downregulated in different models of muscle wasting (74). 
Indeed, when the levels of PGC-1α are maintained, either by the use of transgenic mice 
or by transfecting adult muscle fibers, muscles are protected from the atrophy induced by 
denervation, fasting, or expression of FoxO3 (74, 75, 165). PGC-1α is triggered when the 
energy demand exceeds respiratory capacity, in response to exercise, stress, and ROS 
production (66). PGC-1 also activates the nuclear respiratory factors 2 (Nrf-2) (76), 
thereby driving the transcription of other proteins that are linked with mitochondrial 
health and skeletal muscle homeostasis via the regulation of ROS (79). Excessive 
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mitochondrial ROS are associated with oxidative damage and disease states (150, 167). 
This is supported by studies that utilize mitochondria-targeted antioxidants that have been 





Regulators of cancer related skeletal muscle wasting 
1.1.4 Tumor Factors 
For the last seven decades, there have been attempts to identify and understand 
what secreted factors from tumors signal skeletal muscle atrophy. In this search, various 
cytokines and catabolic factors that could regulate the loss of skeletal muscle mass have 
been identified (108, 112). These pro-inflammatory and pro-catabolic factors are thought 
to be produced by the tumor cells and have important roles in the development of cancer-
related atrophy. For instance, pro-inflammatory cytokines, such as tumor necrosis factor 
alpha (TNF)-α, interleukin (IL)-1, IL-6, and anti-inflammatory cytokine such as IL-10, 
promote the activation of factors associated with muscle wasting. These factors cooperate 
with each other or act alone as drivers of systemic inflammation. The molecular 
mechanisms by which these pro-inflammatory factors may contribute to the development 
of skeletal muscle atrophy have been linked to the activation of various downstream 
molecules in muscle and fat.  
1.1.4.1 Increase Protein break down 
TNF-α has been reported to be upregulated in several forms of cancer (46, 48)  
and is linked to the catabolism of various myofibrillar proteins in the myotubes via 
activation of nuclear transcription factor-kappaB (NF-κB) through IkB kinase signaling 
(71). The activated NF-κB increases the transcription of genes such as MuRF1 that 
specifically degrades myofibrillar proteins such as myosin, contributing to the loss of 
lean body mass during cancer-related atrophy (23, 30, 95). Similarly, IL-6 induces 
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apoptosis in skeletal muscles by increased caspase activity via activation MAPK cascades 
(61, 159).  
1.1.4.2 Reduce protein synthesis 
Along with the TNF-α and IL-6, recent preclinical studies in murine models of 
cancer-related muscle wasting demonstrated that higher levels of IL-10 inhibited protein 
synthesis in skeletal muscles via increased levels of Myc and activation of mTOR 
signaling (4, 134). This link to cancer-related muscle wasting is predominantly based on 
the concept of tumors reprograming host metabolism (44). 
Metabolic reprogramming has been linked with proteolysis-inducing factor (PIF) 
which acts by decreasing protein synthesis through phosphorylation of eukaryotic 
translation initiation factor 2α and accelerating protein degradation through the ubiquitin-
proteasome pathway promoting skeletal muscle atrophy (160, 166). In addition to pro-
inflammatory cytokines, myostatin is another muscle-wasting factor that is secreted by 
the skeletal muscles, adipose tissue, and tumor cells (60, 149, 178). Myostatin acts via 
activin receptor type II-mediated signaling and regulates muscle wasting (37, 109, 161). 
Further to the pro-inflammatory and atrophic factors, cancer-related muscle wasting is 
associated with other host factors such as neuroendocrine stress responses via the release 
of glucocorticoids (158, 163). Though the muscle cells and nervous system crosstalk is 
not fully elucidated, it is thought that this mechanism is complex, and further studies are 




1.1.5 Chemotherapy  
Chemotherapy treatments are a combination of drugs administered in a 
standardized treatment regimen, specific for the cancer type. Various interactive effects 
of different drugs could occur; leading to numerous deleterious consequences to normal 
tissues, including pulmonary toxicity, myotoxicity, mitotoxicity, and cardiotoxicity. How 
these various compounds may induce atrophy in cancer patients is poorly characterized, 
and the breadth of literature on the topic is significantly less than tumor factors. However, 
the direct effects of systemically administered chemotherapeutic agents, which circulate 
to all tissues in the blood, are prime candidates. Non-tumor tissues, including skeletal 
muscle, are exposed to a variety of chemotherapy-related toxic effects over the course of 
treatment with most standard chemotherapy regimens. These include repeated cycles of 
acute exposure to high levels of oxidative stress (24) which disrupt a wide range of 
cellular functions. 
1.1.5.1 Doxorubicin 
Anthracyclines such as doxorubicin are thought to produce their biologic activity 
principally via interaction with topoisomerase II and subsequent double-stranded DNA 
breaks (28, 68, 155), however, defects in mitochondrial biogenesis and the production of 
reactive oxygen (68, 155) has been reported in several studies. Muscle toxicity of 
anthracyclines is mediated through increased production of reactive oxygen species 
(ROS) by muscle mitochondria and increased catabolic processes that upregulate 
MuRF1and impair contractile function (77, 179). 
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Different tissues accumulate anthracycline-induced mitochondrial damage at 
varying rates, in rats defective mitochondrial respiratory enzyme activity and increased 
ROS production are observed in renal (86) tissues, 6–7 months after the end of treatment. 
Existing studies in tissue culture, rodents, and humans show acute negative effects of 
anthracyclines such as doxorubicin on skeletal muscle. Administration of doxorubicin 
induces skeletal muscle mitochondrial ROS, increases proteolysis and leads to muscle 
weakness (53-55). Direct injection of doxorubicin into skeletal muscle causes atrophy, 
and altered myofilament structure humans and rodents (98, 172).  
Cardiac toxicity is also a well-known side effect of anthracycline chemotherapy 
and has been the subject of numerous investigations (85), showing that this cardiotoxicity 
is increased with higher cumulative doses (40). Cardiotoxicity is a dose-limiting side 
effect of doxorubicin (22). 
1.1.5.2 Cisplatin 
Cisplatin is a platinum-based anti-cancer drug common in breast, and lung cancers (35), 
and is thought to interfere with DNA replication, targeting the fastest proliferating cells. 
It has a number of side effects that can limit its use to include nephrotoxicity and 
neurotoxicity, with the former being a dose-limiting side effect (103). The mechanisms 
by which cisplatin affects skeletal muscle, however, are less well described. Cisplatin 
produces significant muscle atrophy in mice, via the activation of NF-κB; however, other 
studies have demonstrated that F-box, MuRF1, and FoxO3 are significantly increased 
with cisplatin treatment (138, 175). These increases of catabolic markers have also been 
linked to transient and acute reduction of protein synthesis in both healthy and tumor-
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bearing mice (139). Both these types of cellular toxicity are potentially relevant in 
initiating changes in muscle tissue which lead to the long-term functional deficits. 
1.1.5.3 Paclitaxel  
Taxane drugs, such as paclitaxel and docetaxel, are chemotherapeutic agents, which work 
by disrupting microtubule function to inhibit cell division. Taxanes have become a 
common agent primarily against breast cancer, metastatic prostate cancer, and non-small 
cell lung cancer due to its efficacy in solid tumors. These drugs are believed to induce 
sensory and motor neuropathy by impairing axon structure and function, most 
specifically by inducing mitochondrial and vascular dysfunction (127). Other side effects 
of taxane treatment are pain in the joints and muscles, occurring 2 to 3 days after 
paclitaxel treatment (52). There are currently no comprehensive studies looking at the 
mechanisms for which paclitaxel or other taxanes may induce skeletal muscle atrophy. 
However, studies have looked at the consequences of impairing microtubule dynamics in 
skeletal muscle. The microtubule cytoskeleton in skeletal muscle resists mechanical 
perturbation acting as a mechanotransducer (27, 151) allowing the cell to respond 
mechanically to the environment. Animal studies have shown that disrupting the tubulin 
dynamics with paclitaxel in skeletal muscle increases cellular ROS and oxidase-
dependent production of ROS (78). Indeed tubulin has been implicated regulating 
mitochondrial bioenergetics and that paclitaxel treatment impaired mitochondrial 
ADP/ATP exchange resulting in greater H2O2 emission kinetics. 
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1.1.5.4 Glucocorticoids  
Drugs such as dexamethasone and prednisone are frequently used for their anti-emetic 
properties around the time of chemotherapy (90, 116, 148). During the administration of 
glucocorticoids, especially prolonged courses or higher doses, skeletal muscle atrophy 
can be expected (8, 14). Additionally, glucocorticoid treatment-related myopathy is 
reported to be more pronounced in proximal muscles and fast twitch (type II) fibers 
(144). There is still research as to whether high dose glucocorticoids contribute to long-
term muscle dysfunction, there is evidence that prolonged corticosteroid use can induce 
muscle mitochondrial dysfunction and increased oxidative damage to both nuclear and 
mtDNA (106).  
1.1.5.5 Other chemotherapies 
Other chemotherapy drugs have also been associated with skeletal muscle 
dysfunction, but evidence of a direct effect on skeletal muscle is currently less 
characterized than the agents discussed above (35, 70). However, there is not yet enough 
clinical follow-up data to know whether these newer drugs also have deleterious long-
term impacts on skeletal muscle or other tissues. Thus, it remains possible that the 
specific agents discussed above, used in the treatment of cancer have a synergistic impact 
on muscle, distinguishing the role of each drug in causing muscle dysfunction in an in 
vivo setting is extremely challenging. Nevertheless, models to help elucidate these 
mechanisms are being utilized. 
  
17  
With the current treatment regimens leading to higher cancer survival rates, we can 
anticipate that these agents will continue to be used, increasing the number of cancer 
survivors. Deficits in skeletal muscle and function have been reported to persist many 
years after successful treatment (19, 176), implicating anti-cancer treatments themselves 






Although cancer treatments, such as chemotherapy, can be efficacious, they can 
lead to long-term side effects such as fatigue, muscle loss, and reductions in functional 
capacity (31). However, currently, there are no effective treatments specifically targeting 
cancer related skeletal muscle atrophy. Cancer-related muscle atrophy is a multi-factorial 
syndrome that may require an approach that targets the different factors involved. 
Historically, clinical interventions and studies have focused on stabilizing and improving 
the nutritional status, finding novel biomarkers, and developing better techniques for the 
estimation of muscle mass. However, there is new interest in exercise training and muscle 
loss prevention in cancer patients (100, 128, 171). Exercise training has an important role 
in skeletal muscle plasticity, acting on several pathways and possessing multifactorial 
effects. Within the muscle, it has anabolic and catabolic effects, it exerts anti-
inflammatory effects, and it has anti-oxidative implications (88). 
1.1.6 Exercise-related mechanisms 
For a skeletal muscle to undergo exercise-specific adaptations, it must both sense and 
transmit the information that is unique to each type of exercise stimulus. The force 
generated in sarcomeres is transferred to the extracellular matrix via focal adhesions, 
where the actin cytoskeleton is connected via linker proteins to the extracellular-matrix-
bound trans-membranous integrins (Figure 5). Changes in mechanical stress are 
responsible for changes in the multiprotein complexes called costameres in skeletal 
muscle involved in mechanotransduction and mechano-sensing (167). The transmission 
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of this information is mediated by signaling pathways that rely on the use of reversible 
posttranslational modifications to transmit information. Physiological stressors that are 
active during exercise have been identified: mechanical load, neuronal activation, 
hormonal adjustments and metabolic disturbances (45). During exercise at a specific 
intensity and over a defined period of time, muscle tissue experiences a particular blend 
of these fundamental stressors (63). With strength training, the mechanical stress is 
dominant, while during endurance exercise, mechanical stress is low but metabolic 
disturbances can protract. A single bout of physical activity/exercise induces muscle 
molecular signaling pathways linked to anabolic/catabolic processes that have 
documented effects on muscle health. Furthermore, repeated bouts of activity can 
stimulate beneficial mechanical adaptations (102). These acute responses and chronic 
adaptations to exercise have utility for improving muscle function (62). 
In healthy groups, a single bout of exercise mechanical stress can stimulate 
protein synthesis, which remains elevated for several hours following contraction (34). 
The duration and extent of this induction can be affected by exercise type (endurance vs 
resistance), intensity and workload of muscle, but have been shown to induce signaling 
through extracellular regulated kinase, stress-activated protein kinase and protein kinase  
such as Akt, and ribosomal S6 kinase (3, 38, 170, 173). In preclinical studies, the ability 
of muscle contraction to induce protein synthesis has implications for cancer-related 
muscle wasting in which Akt/mTORC1 signaling may be disrupted (169). Skeletal 
muscle mass depends on mechanical stresses induced during specific exercise types. 
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Acute exercise can accelerate protein turnover and may serve to replace damaged 
proteins, which is necessary for the maintenance of muscle homeostasis. Repeated 
exercise training can decrease the indices of protein breakdown in muscle, which may be 
related to improved protein quality (16). Additionally, muscle protein breakdown is 
stimulated by both acute endurance and resistance exercise (162, 174) related to the need 
to clear damaged proteins induced by contraction or mechanical loading. Protein turnover 
and homeostasis have been shown in animal models were voluntary running decreased 
Murf1 expression and autophagy protein expression when induced via catabolic 
compounds (126). 
 Muscle oxidative metabolism is also modified with acute and repeated exercise, 
expression of several mitochondrial proteins such as PGC-1α, and Nrf (57) have been 
reported. Evidence also suggests that resistance exercise can improve mitochondrial 
quality and function via mTORC1 inducing muscle PGC-1α protein expression (33) 
increasing mitochondrial gene expression and oxidative function (181). Endurance 
exercise can also positively regulate mitochondrial dynamics through modification of 
fusion and fission protein expression (36). Damaged or dysfunctional mitochondria 
removal has also been identified as an important exercise benefit (180). 
1.1.7 Neuromuscular electrical stimulation 
Exercise is not always possible due to treatment complications or 
contraindications to aerobic exercise and resistive training. Reports suggest that only 
~ 35% of cancer survivors achieve current recommendations (94, 154) with 
breathlessness, fatigue, weakness, and poor balance cited as common issues affecting 
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basic exercise participation such as walking (92). Thus, pragmatic alternatives to 
traditional exercise methods are required. 
Neuromuscular electrical stimulation (NMES) involves controlled muscular 
contractions generated by electrical impulses delivered through surface electrodes, 
usually placed on major muscle groups such as the quadriceps and hamstrings (69). The 
evoked contractions have proven efficacy in improving muscle strength and 
cardiorespiratory fitness across a variety of populations (9, 20, 21, 32). Thus, physician-
supervised NMES exercise to enhance the neuromuscular systems has applicability 
within the cancer population to prevent the complications associated with treatment and 
improve health-related quality of life. However, NMES uptake clinically is low (93) and 
currently, no published, high-level evidence supports its application in cancer 
survivorship. Although experimental evidence in different populations highlights the 
efficacy of NMES, there is a need to evaluate the efficacy in cancer patients and cancer 
survivors before it can be implemented into cancer care pathways. Previous work in 
NMES and cancer has focused on tetanic, muscle strengthening protocols, nonetheless, 
the mechanisms that lead to the reported beneficial effects of NMES is poorly 





Although atrophy is a common outcome of experimental and human cancer cachexia, 
discrepancies in the mechanisms underlying cancer-related muscle wasting have been 
reported between different experimental models as well as in patients with different 
tumor types, with limited available data in humans (71, 111). These differences in 
experimental design and clinical outcomes hinders the development of therapeutic 
strategies and underscore the need for more research on patients and the development of 
pre-clinical models that closely emulate the clinical scenario (123). Currently, most 
clinical trials on cancer-related atrophy have been conducted in patients very advanced in 
their disease trajectory, or in animal models with exaggerated clinical phenotypes lacking 
physiological relevance. This leads to speculation that some reported outcomes are an 
artifact of experimental design or limited clinical evaluation (130). Using a simplified 
system such as a cell line offers advantages in experimental design such as consistency, 
availability, robust cell growth, and simple manipulation. There is the caveat that 
immortalized cell lines often have been cultured for very long periods of time, which may 
lead to changes in normal function. However, these deviations are limited and can be 
mitigated with proper controls, with the additional advantages of reducing animals use 
and easy transfection. Another option for cell culture is the use of primary human skeletal 
cells, however; there are several issues that need to be considered. With primary skeletal 
muscle cells, the amount and source of the tissue can vary, leading to varying results in 
mechanical and biochemical results depending on the fiber types, there is also the limited 
passage capacity of primary cells, and the difficulty in keeping a primary line going. 
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However, the commercially available mouse-derived muscle cell line C2C12 is 
frequently used to study intracellular signaling and function in skeletal muscle cells. 
1.1.8 C2C12 model 
The immortalized cell line designated C2C12 were generated by Blau, Chiu, and 
Webster (11) as a subclone of the C2 cell line isolated by Yaffe and Saxel at the 
Weizmann Institute of Science in Israel in 1977 (177). C2C12 cells were originally 
derived from satellite cells from the thigh muscle of 2-month old female C3H dystrophic 
mice 70 h after a crush injury. The C2C12 cell line differentiates rapidly, forming 
contractile myotubes and producing characteristic muscle proteins. These proteins 
include slow- and fast-twitch skeletal muscle myosin isoforms (132) with fast myosin 
Type IIx the most dominant isoform (18, 146), along with other important sarcomeric 
proteins involved with contracture (121, 168). These cells have similar characteristics to 
those of isolated human skeletal muscle cells (51, 87, 91), and have been utilized in 
several experiments as a model of contraction. 
C2C12 cells are capable of rapid proliferation under high serum conditions and 
can later fuse to form multinucleated myotubes under low serum conditions or starvation, 
leading to the precursors of contractile skeletal muscle cells in the process of myogenesis 
(12). Myogenesis in C2C12 can be controlled by genetic manipulation, making it a 
powerful system for studying muscle development (10). The molecular regulators of 
myogenic differentiation in C2C12 including the paired box transcription factors Pax7 
and the myogenic regulatory factors Myf5, MyoD, myogenin (49, 81), that have been 
used as early markers of differentiation and maturity in myotubes. Studies have shown 
  
24  
that within two days of differentiation, the normal cells form spindle-shaped 
mononucleated myoblasts that are in the process of cell migration and fusion (168). By 4-
5 days, multinucleated myotube networks formed and some ultrastructure such as 
unorganized precursor to sarcomeres are visible (82). By 6-8 days sarcomeres and Z-lines 
could be observed (168) the myofibril content appear to be increased, and the sarcomeres 
are present across the width of myotubes (Figure 4) (99).  By this point in their 
development C2C12 cells demonstrate maturation into functional muscle having the 
ability to contract and generate force (99).   
C2C12 in vitro cells are also a great model for testing physiological stresses, 
determining their relevance and functions to humans (73). Through literature review, it 
was found that the most effective functional assay, due to their differentiation and 
contractile dynamics, is their response to electrical stimulation, since C2C12 myotubes 
when mature express calcium ion channels and are able to trigger the 
contraction/relaxation cycle at various voltages (58). These known characteristics of the 
C2C12 make it a viable cell line to test the effects of exercise/NMES against various 
catabolic environments present during cancer-related atrophy. 
1.1.9 Electrical stimulation in a model system  
C2C12 myotubes can grow on various surfaces when appropriate matrix proteins 
are in place and electrically stimulated with commercially available carbon electrodes 
(50, 117). This system is easy to manipulate and is useful for analyzing the biochemical 
and molecular biological phenomena induced by muscle contraction. However, there are 
fundamental differences between physiological contractions and those evoked by some in 
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vitro STIM protocols. During exercise, muscle contractions are generated due to the 
activation of motor units by action potentials. Moreover, the frequency is modulated to 
match the requested power output, and the motor units in a contracting muscle are not 
simultaneous but alternately activated (107), making it difficult to estimate the duration 
of each stimulus. It is difficult to evaluate which STIM protocol mimics more an 
endurance-type or resistance-type in vivo exercise. An approach to overcome the 
limitation of an undefined STIM protocol was presented by Sciancalepore et al. who 
recorded electromyographs of human gastrocnemius medialis during activity (147) and 
then applied this stochastic STIM pattern to primary myotubes with varied results. As 
novel as this approach was most current STIM studies have used two different 
approaches of either high-frequency protocols with rest periods in-between short pulses 
or with a constant frequency over several hours up to 48 h without resting period (157). 
Either of which does not accurately reflect the in vivo conditions patient muscles are 
exposed to during exercise but do emulate extreme weight lifting or ultra-long distance 
running. Others have applied more exercise relevant STIM methodology of low volts and 
frequency for 30- 60 minutes (72, 114) however, most have not applied it over a multi-
day period, providing only acute results. A STIM protocol that could be implemented 
over several days, to test the chronic effects of exercise, and best emulate in vivo exercise 
conditions was lacking in the literature, and development of one was needed for future 
studies. 
With all the controls in place, there are still limitations to an in vitro STIM 
system, blood flow, and innervation, which are important for feedback regulations to 
meet the metabolic demands of working muscle in vivo cannot be emulated in vitro. In 
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addition, muscle fibers in vivo are in a 3D environment surrounded by connective tissue 
and extracellular matrix, which might affect transcriptional activation of genes in 
contracting cells, as well as protein release (39) which are difficult to replicate in vitro, as 
the exact substrate demand of myotubes subjected to STIM is unknown. Moreover, In 
vivo skeletal muscle is also connected to the skeleton via tendons, and during 
contractions, the mechanical load is applied to the myofibers. Using inappropriate 
conditions or too long stimulation might result in detachment of myotubes, compromised 
cellular integrity, and damage of cells, as outlined above. Although cultured myotubes 
are attached to the surface of the culture dish during STIM, the mechanical load is not 
comparable nevertheless, cell culture allows for the standardization of all these conditions 
allotting for reproducibility. Finally, some side effects of STIM have to be considered, in 





Although the factors that lead to cancer-related muscle wasting are still debated, the 
current paradigm is focused on the pathophysiological state of anabolism and catabolism 
dysregulation, with decreased protein synthesis and increased MuRF1 expression. 
Physical activity and exercise are already thought to be beneficial during cancer treatment 
and holds clear potential as a nonpharmacological treatment for muscle wasting 
conditions. Emerging evidence from preclinical models suggests an interaction between 
increased physical activity/exercise and improvements in muscle mass and mitochondrial 
function, possibly mediated via the contracture of muscle. However, the complexity of 
etiology and the manifestation of the symptoms will likely need a multimodal format 
approach to treatment. Further research is warranted to determine the mechanistic basis 
of these improvements and if these benefits can be achieved with surrogates of exercise 
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Figure 1.0.1: Skeletal muscle structure 






Scheme illustrating the regulation of FoxO via modulation of ROS and the Akt 
pathway. (From: Sandri et al. Fig. 3) (141) 















































Mitochondrial regulation in skeletal muscle (From: Hood et al. Fig. 1) (67) 
 




C2C12 myotube, 8 days post starvation, photographed in culture. Striations suggest 
presence of well-organized myofilaments. (From: McMahon et al. Fig. 1A)(99) 
 





Schematic representation of the intermediate filament (IF) scaffold in 
striated muscle. The IF scaffold, predominantly composed of desmin 
(yellow), links the entire contractile apparatus to the sarcolemma and 
other organelles, such as the nucleus, mitochondria, lysosomes, and 
potentially the sarcoplasmic reticulum (SR). Desmin interacts with 
many other proteins including synemin, paranemin, syncoilin, and 
myospryn. Keratins (K8/K19) link the contractile apparatus to the 
sarcolemma and interact with the dystrophin-dystroglycan (DG) 
complex. Overall, the IF scaffold helps maintain the integrity of 
muscle cytoarchitecture and provide mechanical strength to the cell. 
Abbreviations: MLP, striated muscle-specific LIM protein; SG, 
sarcoglycan, From: Henderson et al. Fig. 3) (64) 
Figure 1.0.5: Schematic representation of the intermediate 






Table 1.1: Common properties of skeletal muscle fiber types 
  Type I Type IIA Type IIX 
Other Names Slow Twitch Fast Twitch 
Fast 
Twitch 
Metabolism Oxidative Oxidative/Glycolytic Glycolytic 
Myosin Heavy Chain MHC I MHC IIa MHC IIx 
mATPase activity Slow Fast Very fast 
Power Weak Intermediate Strong 
Velocity Slow Fast Very fast 
Force Low Intermediate High 
Mitochondrial density High Intermediate Low 
Endurance capacity High Intermediate Low 






List of abbreviations 
 
2-[4-(2-hydroxyethyl) piperazin-1-yl]ethanesulfonic acid HEPES  
Antioxidant response element ARE 
atrogin-1/muscle atrophy F-box MAFbx 
Autophagy Lysosome Pathway ALP 
circulating Atrophy Inducing Factor cAIF 
c-Jun N-terminal kinase JNK 
Conditioned Medium CM 
Cross Sectional Area  CSA 
Dimethyl sulfoxide DMSO 
Dithiothreitol DTT 
Doxorubicin DOX 
Dulbecco´s Modified Eagle´s Medium DMEM 
Electron Microscopy  EM 
extracellular signal-regulated kinase 1/2 ERK1/2 
Fetal Bovine Serum FBS  
GABA(A) receptor-associated protein-like 1 Gabarapl1  
glutathione GSH 
Hank’s balanced salt solution HBSS 
Human biopsy cell line  hTCM 
Interleukin 6 IL-6 
Kirsten rat sarcoma viral oncogene homolog KRAS  
Lewis lung carcinoma LLC 
Lox-Stop-Lox- KRASG12D LSL-KRASG12D  
Manganese superoxide dismutase MnSOD 
mitogen-activated protein kinase MAPK 
Mouse tracheal epithelial cell  MTEC  
Muscle-specific RING finger protein 1 MuRF1 
Myosin Heavy Chain type I MHC I 
Myosin Heavy Chain type II  MHC II 
N-acetylcysteine NAC 
Nicotinamide adenine dinucleotide phosphate NADPH 
non-small cell lung NSCL 
non-small cell lung cancer NSCLC 
Nuclear factor (erythroid-derived 2)-like 2 Nrf2 
nuclear transcription factor kappa B NFκB  
Paclitaxel  TAXOL 
Penicillin-Streptomycin P/S  
Peroxiredoxin 3 Prx 3 
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Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha 
PGC-1α 
Phosphate Buffered Saline PBS  
phosphatidylinositol 3-kinase (PI3-kinase)/protein kinase B Akt 
Proteolysis Inducing Factor PIF 
quality of life QOL 
Quantitative real time PCR qRT-PCR/qPCR 
Reactive oxygen species ROS 
sarcoplasmic reticulum SR 
small cell lung cancer SCLC  
small interfering RNA siRNA 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS PAGE 
superoxide dismutase SOD 
TBS-Tween TBST 
TNF receptor subtype 1 TNFR1 
Tris-buffered saline TBS 
tumor necrosis factor-alpha TNF 
Tumor Necrosis Factor-α TNFα 
Ubiquitin 26S-Proteasome System UPS  
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Tumor-secreted factors are hypothesized to cause fat and skeletal muscle wasting in 
cancer patients. To test this hypothesis, we examined whether tumor cells secrete factors 
to promote atrophy by evaluating the effects of tumor-conditioned media (CM) from 
murine and human lung tumor cells on cultured muscle myotubes. We evaluated two 
murine lung cancer cell lines that produce cachexia in mice, Lewis lung carcinoma (LLC) 
and KRASG12D cells, and primary cell lines derived from tumor biopsies from patients 
with lung cancer (hTCM; n=4). We hypothesized that conditioned media from murine 
and human tumor cells would reduce myotube myosin content, decrease mitochondrial 
content and increase mitochondrial reactive oxygen species production (ROS). Treatment 
of myotubes differentiated for 7 days with CM from LLC and KRASG12D cells did not 
alter myotube myosin content or mitochondrial content or ROS production. Effects of 
murine tumor cell CM were observed, however, when myotubes differentiated for 4 days 
were treated with tumor cell CM and compared to undiluted differentiation media. 
However, these effects were not apparent if tumor cell CM treatments were compared to 
control cell CM or dilution controls. Finally, CM from human lung tumor primary cell 
lines did not modify myosin content or mitochondrial content or ROS production 
compared to either undiluted differentiated media, control cell CM or dilution controls. 
Collectively, our results argue against the hypothesis that lung cancer cell-derived factors 






Cancer cachexia is a syndrome characterized by unintentional loss of both fat and 
skeletal muscle tissue (19) that affects ~50% of patients (18, 60). Patients with solid 
tumors are most likely to experience muscle atrophy, particularly in advanced stages (42). 
Muscle wasting increases treatments side effects (15, 23, 55), decrease response to 
chemotherapy (29, 33, 53) and increases mortality (17). Despite these deleterious 
consequences, the causes of cancer cachexia remain unclear. 
How tumors that are anatomically distal to skeletal muscle cause atrophy is 
unknown. One long-standing theory holds that factors released from tumor cells promote 
tissue wasting, through direct effects on the muscle or indirectly by provoking host-
related factors, such as inflammatory cytokines. Data supporting this theory comes 
primarily from pre-clinical models (2, 37, 47). While these studies have provided a 
wealth of mechanistic data, their translatability to human cancer remains questionable. In 
animal models, tumors grow rapidly and comprise a large fraction of body mass (7). For 
instance, in the C26 xenoplant model, the onset of cachexia typically occurs when the 
tumor reaches ~5% of body mass (56), which occurs 2-4 weeks after inoculation (10, 30). 
Extrapolated to humans, the size of this tumor would equate to an ~8 lb. tumor in men 
and ~6 lb. tumor in women. Accordingly, the pathoetiology of cachexia in these pre-
clinical models may be skewed disproportionately towards tumor-derived factors. In 
contrast, human tumors develop relatively slower and comprise <<1% of body mass. In 
this context, cancer cachexia in humans may be less dependent on tumor-derived factors 
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and/or factors derived from tumor cells may be less effective at promoting muscle 
wasting and cachexia. 
A common model for testing the effect of tumor-derived factors on skeletal 
muscle involves treating cultured muscle cells with conditioned media (CM) from tumor 
cells (11, 21, 52, 58, 59). Conditioned media experiments provide a more focused model 
to examine the direct effects of tumor-derived factors on skeletal muscle. Data from these 
approaches using various cell lines support the notion that tumor-derived factors promote 
skeletal muscle atrophy (38, 63, 64, 69). In the current study, we sought to use this model 
to examine the effects of lung cancer cell-derived factors on skeletal muscle. We chose 
lung cancer because these patients experience a high prevalence of cachexia (6) and 
because lung cancer is a common model used for pre-clinical cancer cachexia studies. We 
utilized CM from two murine lung tumor cell lines: the Lewis lung carcinoma (LLC) and 
KRASG12D cell lines. The former potently induces cachexia in mice (48, 69) and is used 
widely in the field. The latter contains the most frequently occurring mutation in human 
non-small cell lung tumors (62) and provides a near genetically identical cell line for 
control studies. Additionally, we report, for the first time to our knowledge, the effects of 
CM from primary cell lines derived from clinical biopsies of human lung tumors. We 
tested the effects of CM from these cells on differentiated C2C12 myotubes. Myotubes 
were differentiated for 7 days prior to treatment with CM, a time when they develop 
anatomical and physiological attributes similar to in vivo skeletal muscle and demonstrate 
atrophy in response to myotoxic chemotherapeutics, such as anthracyclines (24). Based 
on prior work in the field using these and other cell lines, we hypothesized that CM from 
murine and human tumor cells would reduce myotube myosin content, decrease 
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C2C12 myoblasts (ATCC® CRL-1772™, Manassas, VA) were cultured in low glucose 
(1 g/L), Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS; Gibco™ Thermo Fisher Scientific Waltham, MA) and antibiotics 
(50 U/ml penicillin and 50 μg/ml streptomycin). Cells were plated (2 X 104 cells/cm2) on 
Matrigel (60 μg/cm2; Corning, Bedford, MA) and switched to differentiation media (DM) 
of low serum (1% heat-inactivated FBS), high glucose (4.5 g/L) DMEM when they 
reached 90-100% confluence to induce differentiation, as described (32).  
Lewis lung carcinoma (LLC; ATCC CRL-1642) cells, a murine lung cancer cell line that 
promotes cachexia in mice (46), were cultured, as described (21). Briefly, 2 X 105 LLC 
cells were plated on 10-cm diameter culture dishes in DMEM, supplemented with 10% 
FBS, 50 U/ml penicillin and 50 μg/ml streptomycin, and grown for 48 h to a final density 
of 0.8–11 X 106 cells per culture dish. NL20 (ATCC CRL-2503) cells were used as a 
control cell line for LLC cells, as they are non-tumorigenic and have been used as 
controls for LLC CM treatment of C2C12 myotubes previously (70). NL20 cells were 
grown, as described (21). Briefly, 2 X 105 NL20 cells were plated into 10-cm diameter 
culture dishes in DMEM, supplemented with 10% FBS, 50 U/ml penicillin, and 50 μg/ml 
streptomycin, and grown for 48 h to a final density of 0.8–11 X 106 cells per dish. For 
both LLC and NL20 cells, CM from this 48 hr growth period was collected, centrifuged 
to remove cell debris and stored at -80°C until use.  
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Primary mouse tracheal epithelial cells (MTECs) were isolated from 14 week old male 
and female LSL-KRASG12D (The Jackson Laboratory #008179), as described (28). The 
LSL-KRASG12D mice were generated by crossing CCSP-rtTA (The Jacksons Laboratory 
CCSP-rtTA #006222) and TetO7-Cre (The Jacksons Laboratory #006224) bi-transgenic 
mice, to create CCSP-rtTA/TetO-Cre/LSL-KRASG12D mice, as described (1). Cells were 
cultured on collagen-coated plates in DMEM/F12 media containing 10 μg/ml cholera 
toxin (Sigma), 2 mg/ml insulin (Roche), 2.5 mg/ml transferrin (Sigma), 12.5 mg/ml 
bovine pituitary extract (Invitrogen), 10 μg/ml epithelial growth factor (Calbiochem), 50 
μM dexamethasone (Sigma), U/50 μg/ml p/s (Gibco), 4.5 mM L-glutamine (Invitrogen), 
and 1 ml Primocin (InvivoGen), as described (1). MTECs were either treated with a Cre 
recombinant adenovirus to activate the oncogenic KRAS mutation (KrasG12D) or an 
empty vector (KrasWT), which serves as a control cell line. Cells were then washed and 
cultured in serum free media for 2 days and the media was collected, centrifuged to 
remove cell debris and stored at -80°C until use.  
To obtain human tumor cell CM, lung tumor cells obtained from patients during clinical 
evaluations were used to establish primary cultures, as described (43), with 
modifications. Briefly, tissue obtained from the biopsy was treated with elastase and 
DNAse, and then cultured in RPMI 1640 supplemented with L-glutamine and HEPES on 
collagen-coated dishes. Primary broncheal/tracheal endothelial cells (HBEC; ATCC, 
PCS-300-010) (2.5 × 10^5 cells/cm2) were used as a non-cancer cell line. They were 
cultured as adherent monolayers in minimum essential media (MEM) (Invitrogen; 
Carlsbad, CA) supplemented with 9% FBS (Invitrogen), 2 mM L-glutamine, 100 U 
penicillin and 100 μg/mL streptomycin (Sigma-Aldrich; St. Louis, MO). For both 
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primary tumor and HBEC cells, CM was collected following 24 hr incubation in RPMI 
1640 + 9% FBS, centrifuged to remove cell debris and stored at -80°C until use. 
Preparation of CM and HBSS dilution control.  
One volume of tumor or control cell CM was mixed with three volumes of serum-free 
DMEM to treat myotubes. In all cases, serum content was standardized so that both CM 
diluted and undiluted DM treatments had the same final serum concentration (2.5% for 
LLC and NL20 cells; 1% for KrasG12D and KrasWT cells and 2.25% for human tumor and 
HBEC cells). We also included a dilution control to our experiments, which consisted of 
DM diluted 1:3 with Hank’s balanced salt solution (HBSS; 1 g/L glucose). Thus, we have 
4 treatment groups in each experiment: untreated controls (undiluted DM; i.e., no CM 
added), dilution control (1:3 dilution of HBSS:DM), non-tumorigenic/cachectic cell CM 
control (1:3 dilution of CM:DM) and tumor cell CM (1:3 dilution of CM:DM). In all 
conditions, media was changed daily during the 3-day treatment period. 
Patients 
 Patients (76 ± 7 yr; Table 1 for details) with known or suspected lung cancer were 
recruited from the University of Vermont Medical Center Lung Multi-disciplinary Clinic. 
Written informed consent was obtained from all volunteers prior to their participation and 
protocols were approved by the Committees on Human Research at the University of 
Vermont. Tumor cells were obtained when patients underwent either clinically indicated 
bronchoscopy or percutaneous biopsy. Following on-site cytopathological diagnosis of 





Protein expression was measured by western blot. Myotubes were washed with phosphate 
buffered saline, lysed (50 mM Tris, 150 mM NaCl, 10% (v/v) glycerol, 0.5% IGEPAL 
CA-630,1 mM EDTA, containing Protease Inhibitor Cocktail (1:100, cat# P8340, Sigma) 
and Phosphatase Inhibitor Cocktail 3 (1:100, cat# P0044, Sigma), incubated on ice for 30 
min and then centrifuged at 14,000 × g at 4 °C for 10 min. Lysate protein contents were 
measured (BioRad DC Protein Assay, Hercules, CA) and diluted in sample prep buffer 
(62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 1% SDS 0.005% bromophenol blue, 5% 2-
mercaptoethanol). Proteins were separated by SDS-PAGE (Bio-Rad, Hercules, CA, 
USA), transferred to polyvinylidene (PVDF) membranes and blocked with TBST buffer 
(150 mM NaCl, 0.05 % Tween-20, and 20 mM Tris-HCl, pH 7.4) containing 5% non-
fatty milk or BSA. After blocking, membranes were incubated overnight with myosin 
primary antibody (1:20000, Sigma M4276, RRID: AB_477190). Membranes were 
washed for 30 min in TBST and then incubated for 1 h at room temperature in 5% milk-
TBST containing Anti-Mouse IgG-Peroxidase (1:15000, Sigma A2304, RRID: 
AB_257993) secondary antibody with Clarity Western ECL Substrate (Bio-Rad, 
Hercules, CA, USA). 
 
Myotube mitochondrial content and reactive oxygen species (ROS) production 
Mitochondrial content and ROS production were measured with fluorometric dyes, as 
described (25). Briefly, C2C12 myotubes grown in 35 mm dishes or black-walled 96 well 
plates were loaded with fluorescent dyes to assess mitochondrial content (1 μM 
MitoTracker Green FM; 490/516 nm) and ROS production (1 μM MitoSOX Red; 
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510/580 nm; both Molecular Probes, Eugene, OR) 15 minutes prior to measurement. 
Fluorescence was measured on a microplate reader (BioTek, Winooski, VT) and the 
MitoSox signal was expressed relative to MitoTracker signal to control ROS production 
for mitochondrial content.  
 
Statistics  
Analysis of variance (ANOVA) was used to compare treatments. Most studies examining 
CM treatment have compared CM application to a single control condition. Thus, we also 







Characteristics of C2C12 myotube cultures. C2C12 myotubes were differentiated for 7 
days before treatment with CM. Under our culture conditions, there is rapid growth and 
accumulation of myosin between d3 and d7, followed by a relative plateauing of myotube 
myosin content and diameter (data not shown). At d7, myotubes express myofilament 
proteins, including myosin, actin, and α-actinin, and organize these proteins into 
myofilaments (data not shown). Myofilaments and components of the excitation-
contraction coupling system are functional at this time, as electrical field stimulation 
causes intracellular Ca2+ cycling and contraction, which can be prevented by 
pharmacological inhibition of excitation contraction coupling with the sodium channel 
blocker tetrodotoxin (data not shown). Thus, at this stage of differentiation, myotubes 
exhibit numerous hallmark characteristics of in vivo muscle. 
 LLC and Kras CM.  We began by testing the effects of LLC CM, as this cell line is 
widely used to promote cachexia in mouse xenoplant models (4, 8, 11). In C2C12 
myotubes differentiated for 7 days, we found no differences in myosin content among 
LLC CM, HBSS dilution control and NL20 control CM and untreated controls (Figure 
1A) when analyzed via ANOVA. Moreover, because many studies only compare LLC 
CM to a single control, we also performed pairwise comparisons between LLC CM and 
different control conditions (untreated control, HBSS dilution control or NL20 control) 
by unpaired t-tests. There were still no effects of LLC CM on myotube myosin content 
with this different analytical approach. We found an effect of KrasG12D CM on myotube 
myosin content (Figure 1B), but it paradoxically increased myosin content compared to 
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all control conditions (P=0.002) using either ANOVA or pairwise analytical approaches 
(P<0.01).  
Timing of CM application. Reasons for the absence of effects of CM are uncertain, but 
one difference between our protocol and the majority of studies in the field is that we 
used myotubes that were differentiated for 7 days prior to CM application. Most studies 
have treated myotubes at day 4 or 5 post-differentiation. Thus, we also examined the 
effects of CM on myotubes starting at day 4 post-differentiation. Under these conditions, 
we observed a 32% reduction in myosin content (P<0.05 using either ANOVA or 
pairwise analytical approaches) in response to LLC CM compared to untreated control 
(Figure 2A). However, a similar reduction in myosin content was noted with CM from 
the non-tumorigenic NL20 cell line (33%, P<0.05 using either ANOVA or pairwise 
analysis) and a trend for lower myosin content was observed in the HBSS dilution control 
(P=0.07 pairwise analysis, P=0.08 ANOVA) compared to untreated controls (Figure 2A). 
Similarly, using Kras CM administered at day 4 post-differentiation, we found a 36% 
reduction in myosin content with KrasG12D CM (P<0.05 ANOVA or pairwise analysis). 
However, we also observed a reduction 38% in myosin content with CM from KrasWT 
cells (P<0.05 ANOVA or pairwise analysis) and 39% reduction with the HBSS dilution 
control (P<0.05 ANOVA or pairwise analysis) when compared to untreated controls 
(Figure 2B).  
Mitochondrial content and ROS production with murine CM.  Recent reports have 
suggested a role for oxidant stress in the atrophic effect of tumor-related factors (3, 16, 
20, 31, 60). Thus, we examined the effects of CM on mitochondrial content and ROS 
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production. LLC treatment of myotubes 7 days post-differentiation did not alter 
mitochondrial ROS production (Figure 3A), nor did treatment with any of the control 
conditions, whether we utilized ANOVA or pairwise comparisons. Mitochondrial content 
was also unchanged with HBSS, NL20 or LLC treatment (Figure 3B). With Kras 
experiments on day 7 post-differentiation myotubes, there was no change in ROS 
production compared to untreated controls (Figure 3C), but both KrasG12D (P<0.01 
ANOVA or pairwise analysis) and KrasWT (P<0.01 ANOVA or pairwise analysis) CM 
increased mitochondrial content (P<0.01; Figure 3D) when measured with ANOVA or 
pairwise comparisons.  
When LLC CM was applied to d4 myotubes, no changes in ROS were found 
(Figure 4A). However, mitochondrial content was elevated with NL20 CM (P<0.01 
ANOVA or pairwise analysis) (Figure 4B). Kras CM increased ROS production in d4 
myotubes with both KrasG12D (P<0.01) and KrasWT (P<0.01) CM (Figure 4C), but not 
with HBSS control dilution. Mitochondrial content was also increased by KrasG12D 
(P<0.01) and KrasWT (P<0.01) CM (Figure 4D) relative to untreated controls when 
measured with either ANOVA or pairwise analysis. 
Myotube myosin content with human CM. Informed by the results of LLC and Kras 
studies, we decided to test CM from patient lung cancer biopsies on d7 myotubes, as we 
reasoned that effects of CM observed on d4 myotubes were due to growth inhibition, 
rather than a unique effect of tumor-derived factors on myotubes. We treated d7 
myotubes with patient tumor CM from 4 patients (human tumor conditioned media; 
hTCM), non-cancer control cells (human bronchial epithelial cells; HBEC), HBSS 
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dilution controls, and untreated controls for 3 days with serum content constant among all 
groups. We found no effect of patient lung tumor primary cell CM on myosin content 
compared to untreated and saw no reduction with any of the treatment groups (Figure 
5A). Similarly, we found no effect of patient lung tumor primary cell CM, non-cancer 
control cell CM or dilution control compared to untreated control (Figure 5B). We 
observed an effect of hTCM (+19%, P<0.01) and HBEC CM (+16%, P<0.05) to increase 
mitochondrial content compared to untreated controls, but no effect of HBSS dilution 





Conventional wisdom holds that tumors release soluble factors that act on distal 
skeletal muscle tissue to cause atrophy and other metabolic derangements in cancer 
patients. We evaluated this proposition by testing the effects of murine and human lung 
tumor cell CM on C2C12 myotube cultures, a common model to test for tumor cell-
derived atrophic factors (11, 35, 36, 38, 44, 51, 68). Our studies included controls to 
account for dilution of media, factors released into media by growing cells and the timing 
of CM application relative to the start of differentiation. When we examined the effects 
of murine lung tumor cell CM 7 days post-differentiation, when myotubes express 
structural and functional phenotypes common to in vivo skeletal muscle, we found no 
atrophic effects of murine tumor CM on myotubes. Although murine lung tumor cell CM 
reduced myosin content and caused mitochondrial adaptations when applied to myotubes 
differentiated for 4 days compared to untreated controls, similar effects were observed 
with control cell CM and HBSS dilution controls. Finally, to our knowledge, we present 
the first report of the effect of CM from primary cultures of human lung tumor cells on 
cultured myotubes. Similar to murine cancer cell CM, however, we found no evidence for 
an effect of human tumor CM on myotubes. Our results argue against the hypothesis that 
factors released from tumor cells contribute to skeletal muscle atrophy and mitochondrial 
abnormalities.  
Cultured muscle cells are a unique and valuable system that permits examination 
of muscle in isolation, with the ability to manipulate the extracellular environment. 
Despite these strengths, studies in cultured muscle cells are criticized because of the 
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artificial nature of this system. While a myotube is not a perfect model of a muscle fiber, 
how well this system models in vivo muscle may vary depending on its stage of 
differentiation. Treatment of myotubes with either murine or human tumor cell CM 
starting at 7 days post-differentiation had no effect on either myotube myosin content or 
mitochondrial content/ROS production compared to untreated controls. In fact, in the 
case of KRASG12D cells, CM paradoxically enhanced myotube myosin and mitochondrial 
content compared to untreated controls. In contrast to results on 7 day differentiated 
myotubes, CM had effects on cells treated at 4 days post-differentiation, causing myosin 
depletion and some mitochondrial adaptations. The failure to observe effects at 7 days 
post-differentiation is unlikely related to the cell lines used, as LLC is well-proven to 
cause cachexia when transplanted into mice (12, 34, 45, 65) and when LLC CM has been 
applied to cultured myotubes (21, 36, 38, 39, 67). KRASG12D is less well-described, but 
data from our labs (unpublished data) and others show that KRASG12D mice experience 
muscle atrophy (40). One could argue that myotubes at this later developmental stage are 
recalcitrant to atrophic stimuli. However, the application of various chemotherapeutics 
provokes atrophy at this time (24), in agreement with studies by other laboratories on 
myotubes studied earlier following differentiation (22).  
Our data from experiments treating 4-day differentiated myotubes with LLC and 
KRASG12D CM argue that a dilution effect caused by the addition of the CM to standard 
DM impairs myotube growth. Numerous studies have shown that C2C12s are still 
increasing in size and myosin content from day 4 to day 7 post-differentiation (13, 14, 26, 
41, 54, 57, 61). Media dilution with CM may simply starve cells of nutrients required for 
normal growth. A recent study by Jackman et al. supports this interpretation (27). In this 
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study, 4 -day post-differentiation myotubes were treated for 3 days with tumor cell CM 
and compared to untreated DM, similar to the current study. Time course data show that 
the effect of CM was not to induce atrophy but to impair the growth of myotubes. Our 
HBSS dilution control further supports the effects of the CM dilution on myotube growth. 
Thus, we conclude that compared to control cells maintained in undiluted DM, the effects 
of tumor cell CM on 4 day differentiated myotubes primarily reflects growth inhibition. 
If media dilution impairs myotube growth, a more valid control would be a cell 
type similar to the tumor cell line, but that does not release factors that cause muscle 
wasting. Because the identity of these secreted factors is unknown, the selection of 
appropriate control cell lines is difficult. We used CM from a similar lung epithelial cell 
type compared to tumor cell lines. In the control for LLC CM, we used the non-
tumorigenic NL20 cells (21, 49, 50, 71), which is used widely in the field as a control for 
LLC CM (66, 68, 69). This is not an ideal cell line because of species differences, but it is 
non-tumorigenic in animals and grows well under similar media conditions as LLC cells 
and has been used as a control for LLC CM in past studies (46, 70). 
Concern about the appropriateness of the control cell line is lessened in the Kras 
CM experiments, where we used a Cre recombinant adenovirus to activate the oncogenic 
KRAS mutation (KrasG12D) or treatment of cells with an empty vector as a control 
(KrasWT). Thus, with the exception of Cre expression and transgene activation, the 
KrasWT cells are identical to KrasG12D cells. CM from KrasWT controls, therefore, should 
reflect the effects of nutrient depletion, secreted factors and/or metabolic by-products 
typical to growing cells, only differing from KrasG12D CM for those secreted factors that 
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contribute to cachexia. As with LLC CM experiments, data from these controls largely 
mirrored that of HBSS dilution controls and KrasG12D CM, further supporting the 
conclusion that most of the effects of tumor cell CM observed in prior work is related to a 
dilution effect when comparisons are made to cells maintained in untreated (i.e., 
undiluted) control media. Thus, our data collectively argue against the hypothesis that 
factors secreted from tumor cells act directly on skeletal muscle cells to provoke atrophy 
and mitochondrial maladaptations. 
Several caveats to our studies deserve discussion. First, we are examining the 
direct effects of CM on skeletal muscle. Muscles contain an array of other cell types 
(immune cells, satellite cells, fibroblasts, etc.) that could respond to tumor-derived factors 
to provoke atrophy. For instance, tumor CM may mediate its effects through host 
inflammatory response to tumor presence, either systemically or locally within the 
muscle (5, 9). Our experiments did not test potential host-specific host-derived factors. 
Second, we used the common 1:3 dilution of DM with CM to treat the cultured 
myotubes. The amount of secreted factors in this dilution, and the fact that we exposed 
myotubes to a single bolus of the CM (media changed daily), may be insufficient to 
promote skeletal muscle myotube atrophy. To the first point, considering the relatively 
small size of most human tumors relative to the systemic circulation and interstitial fluid 
volumes, such a dilution would seem far in excess of what skeletal muscles are exposed 
to in vivo. To the latter point, recent studies have argued that co-culture of tumor cells 
and muscle myotubes is required to observe a true atrophic effect of tumor-secreted 
factors to cause atrophy (27). While this may be the case, as we have demonstrated with 
our various control conditions, appropriate control cell lines are needed to assure that 
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myotube atrophy is not provoked by media substrate depletion and/or accumulation of 
metabolic waste products. Finally, our model is uncoupled from the complex clinical 
condition present in cancer patients, such as pulmonary insufficiency, chemotherapeutics 
and muscle disuse. The effects of these clinical factors may cause skeletal muscle to be 
more responsive to tumor-related factors that incite muscle wasting.  
In summary, we found no evidence that tumor-secreted factors influence skeletal 
muscle. Although the common experimental model of using 4 day differentiated 
myotubes for treatment yielded lower myotube myosin content compared to untreated 
controls, these decreases were not apparent when compared to controls for media dilution 
or other secreted factors, suggesting that CM effects are most likely related to media 
dilution and growth inhibition, rather than atrophy. Finally, to our knowledge, this is the 
first report of the effects of human tumor primary cell CM on cultured myotubes. Similar 
to results from murine tumor cell CM, we found no effect of human tumor cell CM on 
myotube myosin content or mitochondrial content or ROS production.  Collectively, our 
results argue against direct effects of tumor secreted factors on skeletal muscle to cause 
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Figures & Tables 
 
Figure 1. Effects of 3 d of murine LLC (A; gray bar) or KrasG12D (B; gray bar) 
conditioned media (CM; 1:3) treatment on myosin content in d7 differentiated myotubes 
compared to undiluted (CTRL; open bars), dilution (HBSS; 1:3; hatched bar) and non-
tumorigenic (NL20 and KrasWT cells; 1:3; hatched bars) controls. (A) No effect of LLC 
CM was found compared to CTRL or non-tumorigenic NL20 or HBSS controls (n=6/bar). 
(B) KrasG12D CM increased myotube myosin content compared to CTRL and both 
KrasWT and dilution controls (n=6/bar). Representative gel images are shown at the top 
of panels A and B for a subset of replicates. All data are mean ± SEM, with individual data 
points shown with each bar. **, P<0.01. 
 
Figure 2.0.1: The effects of murine CM on d7 myotubes. 
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Figure 2. Effects of 3 d of murine LLC (A; gray bar) or KrasG12D (B; gray bar) 
conditioned media (CM; 1:3) treatment on myosin content in d4 differentiated myotubes 
compared to undiluted (CTRL; open bars), dilution (HBSS; 1:3; hatched bar) and non-
tumorigenic (NL20 and KrasWT cells; 1:3; hatched bars) controls. (A) LLC and NL20 CM 
reduced and HBSS tended to reduce myotube myosin content compared to CTRL. (B) 
KrasG12D and KrasWT CM and HBSS reduced myotube myosin content compared to 
CTRL. Representative gel images are shown at the top of panels A and B for a subset of 
replicates. All data are mean ± SEM, with individual data points shown with each bar.*, 
P<0.05; †, P<0.10. 
 
 
Figure 2.0.2: The effects of murine CM on d4 myotube myosin. 
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Figure 3.  Effects of 3 d of murine LLC (A and B; gray bar) or KrasG12D (C and D; gray 
bar) conditioned media (CM; 1:3) treatment on mitochondrial reactive oxygen species 
(ROS) production and mitochondrial content in d7 differentiated myotubes compared to 
undiluted (CTRL; open bars), dilution (HBSS; 1:3; hatched bar) and non-tumorigenic 
(NL20 and KrasWT cells; 1:3; hatched bars) controls. No differences were found between 
LLC or NL20 CM or HBSS dilution or untreated (CTRL) controls for mitochondrial ROS 
(A) or content (B) (n=12/bar). (C) No differences were found between KrasG12D and 
KrasWT CM or HBSS dilution or untreated (CTRL) controls for mitochondrial ROS 
(C)(n=12/bar). (D) Both KrasG12D and KrasWT CM increased mitochondrial content 
compared to HBSS and CTL conditions (n=12/bar). All data are mean ± SEM, with 







Figure 2.0.3 The effects of murine CM on d7 myotube mitochondria 
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Figure 4. Effects of 3 d of murine LLC (A and B; gray bar) or KrasG12D (C and D; gray 
bar) conditioned media (CM; 1:3) treatment on mitochondrial reactive oxygen species 
(ROS) production and mitochondrial content in d4 differentiated myotubes compared to 
undiluted (CTRL; open bars), dilution (HBSS; 1:3; hatched bar) and non-tumorigenic 
(NL20 and KrasWT cells; 1:3; hatched bars) controls. No differences were found between 
LLC or NL20 CM or HBSS dilution or untreated (CTRL) controls for mitochondrial ROS 
(A)(n=12/bar). (B) NL20 CM increased mitochondrial content compared to LLC, HBSS 
or CTRL conditions (n=12/bar). Both KrasG12D and KrasWT CM increased 
mitochondrial ROS production (C) and content (D) compared to either HBSS dilution or 
untreated (CTRL) controls (n=12/bar). All data are mean ± SEM, with individual data 












Figure 5. Effects of 3 d of treatment with primary human tumor cell conditions media 
(hTCM; 1:3; gray bars) on myosin protein content (A) and mitochondrial reactive oxygen 
species (ROS) production (B) and content (C) in d7 differentiated myotubes compared to 
undiluted (CTRL), dilution (HBSS; hatched bars) and primary human bronchial epithelial 
cell (HBEC; 1:3 dilution; hatched bars) controls. No differences were found between 
treatments for myotube myosin content (A) or mitochondrial ROS production (B) (n=12-
24/bar). (C) Both hTCM and HBEC increased mitochondrial content compared to HBSS 
dilution and untreated (CTRL) controls (n=12-24/bar). All data are mean ± SEM, with 




Table 2.1: Physical and disease characteristics in cancer patients 
 
   
n 4 
Age (yr) 76 ± 7  
Sex (M/F) 1,3 
BMI 
 23.5 ± 
4 
Weight loss Reported 
0 
Cancer Stage (I/II/III/IV) 0,1,1,1 
Diagnosis (n)  
NSCLC 3 
SCLC 1 
Histology (n)  
Adenocarcinoma 2 
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How breast cancer and its treatments affect skeletal muscle is not well defined. To 
address this question, we assessed skeletal muscle structure and protein expression in 13 
women diagnosed with breast cancer, who were receiving adjuvant chemotherapy 
following tumor resection, and 12 non-diseased controls. Breast cancer patients showed 
reduced single muscle fiber cross-sectional area (CSA) and fractional content of both 
sub-sarcolemmal and intermyofibrillar mitochondria. Drugs commonly used in breast 
cancer patients (doxorubicin and paclitaxel) caused reductions in myosin expression, 
mitochondrial loss and increased reactive oxygen species (ROS) production in C2C12 
murine myotube cell cultures, supporting a role for chemotherapeutics in the atrophic and 
mitochondrial phenotypes. Additionally, concurrent treatment of myotubes with 
mitochondrial-targeted antioxidant (MitoQ) prevented chemotherapy-induced myosin 
depletion, mitochondrial loss, and ROS production. In patients, reduced mitochondrial 
content and size, and increased expression and oxidation of peroxiredoxin 3, a 
mitochondrial peroxidase, were associated with reduced muscle fiber CSA. Our results 
suggest that chemotherapeutics may adversely affect skeletal muscle in patients and that 
these effects may be driven through effects of these drugs on mitochondrial content 
and/or ROS production. 
 





Cancer and its treatment can affect skeletal muscle. The most widely studied 
consequence is cachexia, a syndrome characterized by fat and skeletal muscle tissue 
depletion that typically occurs in late-stage disease (17). Most studies have evaluated 
skeletal muscle from patients with cancers that are prone to cachexia and model systems 
that mimic them. However, patients with other cancer types less prone to cachexia, or 
those with early-stage disease, may also experience muscle atrophy (21) and dysfunction. 
Despite the fact that these patients comprise the majority of cancer survivors, our 
understanding of the effect of these cancer types and their treatments on skeletal muscle 
is limited. 
 
Breast cancer, the most commonly diagnosed cancer in the US (1), is thought to have 
minimal effects on skeletal muscle because patients are less prone to cachexia (16) and 
are typically weight-stable or gain weight during treatment (30). This constancy in body 
weight, however, belies reciprocal changes in body composition, specifically a gain in fat 
and a loss of lean tissue (21). Muscle atrophy and the resulting weakness have prognostic 
importance in breast cancer patients (6, 9, 60), underscoring the need to better understand 
the effects of this cancer type and its clinical sequelae on skeletal muscle.  
 
In the present study, our objective was to examine skeletal muscle in patients receiving 
adjuvant chemotherapy following tumor resection and in healthy controls without a 
history of cancer. We hypothesized that cancer therapeutics might promote skeletal 
muscle adaptations in patients, as drugs commonly used in breast cancer, such as 
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anthracyclines, cause muscle wasting and dysfunction in pre-clinical models (22, 25, 43), 
whereas breast cancer tumors do not (27, 61). More specifically, we hypothesize that 
chemotherapeutics have myotoxic effects through their ability to provoke mitochondrial 
dysfunction and oxidative stress, as studies suggest that mitochondrial remodeling and 
oxidant stress promote skeletal muscle atrophy (48, 51). To begin to address this 
possibility, and building on pre-clinical studies showing that chemotherapeutics have 
effects on mitochondrial biology (3, 43), we also assessed mitochondrial 
content/morphology and markers of oxidative stress. Finally, we employed the C2C12 
murine muscle cell line, as we could not ascribe muscle morphological and mitochondrial 
phenotypes in humans to chemotherapeutics because of the complex clinical background 
of these patients and our case-control study design. Cultured muscle cells provide a 
model where the singular effect of chemotherapeutics can be evaluated independent of 
clinical factors associated with treatment in patients, as well as effects on other tissue and 
organ systems. This latter point is particularly relevant to anthracyclines, which cause 
cardiac damage and heart failure in animal models (26), a syndrome that could affect 
skeletal muscle (54). Though there are the limitations of C2C12 myotube cultures, results 
from these experiments can be used as proof-of-principle evidence that 
chemotherapeutics may have effects on skeletal muscle to provoke phenotypes observed 





Subjects. Thirteen women with breast cancer were recruited. Patients were included if 
they had stage I, II or III, histologically documented breast cancer and were receiving or 
scheduled to receive chemotherapy following surgical resection. We excluded patients 
with prior history of cancer, other than non-melanoma skin cancer, prior 
chemotherapeutic use, autoimmune, vascular or neuromuscular disease or prior knee or 
hip replacement surgery. All patients received dexamethasone for 1 to 4 days concurrent 
with chemotherapy administration to prevent adverse drug reaction and diminish cancer-
induced nausea and vomiting. Patients could receive a maximum dose of 12 mg on the 
day of chemotherapy and 4 mg per day for 3 days thereafter as symptoms necessitate. As 
dosing was symptom-dependent and not tracked clinically, exact doses for 
dexamethasone treatment are not available. Three patients were characterized as having 
experienced weight loss, defined as self-reported, unintentional weight loss >5% of body 
weight within 6 months prior to evaluation; whereas, other patients who reported little or 
no weight change (<5%) were characterized as weight stable. All patients were tested 
during adjuvant chemotherapy, prior to radiation therapy. One patient reported current 
tobacco use (44 pack year history). None of the patients received nutritional support or 
anabolic therapy or were taking medications known to influence skeletal muscle size or 
function aside from chemotherapeutics. One volunteer was on a stable regimen of HMG 
CoA reductase inhibitor, which our recent work suggests would not affect the variables 




Healthy female controls (n=12) were recruited if they were free from acute or chronic 
disease, based on medical screening and routine clinical/laboratory tests, and had no prior 
history of cancer, chronic lung or cardiovascular disease, neurological or orthopedic 
conditions, or other mobility-limiting ailments. Volunteers were excluded if they were a 
current or previous smoker or were taking medications that could influence skeletal 
muscle, with the exception of stable HMG CoA reductase inhibitor treatment (n=1). 
Plasma creatine kinase levels were within the normative range in this volunteer and she 
reported no muscle symptoms. Written informed consent was obtained from all 
volunteers prior to their participation and protocols and procedures were approved by the 
Committees on Human Research at the University of Vermont. 
 
Total and regional body composition. Body weight was measured on a digital scale 
(ScaleTronix, Wheaton, IL). Total and regional body composition was measured by dual 
energy x-ray absorptiometry, as described (57). 
 
Muscle tissue processing. Percutaneous biopsy of the vastus lateralis was performed at 
the mid-way point between the most proximal aspect of the patella and the inguinal fold. 
The skin was sterilized (2% chlorhexidine/70% isopropyl alcohol) and local anesthetic 
(1% lidocaine) infiltrated into the site, as described (55). A small incision (~5 mm) was 
made through the skin, fat and fascia and the biopsy needle (5 mm Bergstrom) advanced 
past the fascia into the muscle at an angle approximately 30-45° to the skin surface to 
position the needle roughly parallel with the muscle fascicles, as described (15), to collect 
long, intact bundles of fibers. Suction was applied and tissue was excised. Tissue for 
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electron microscopy (EM) was tied to a glass rod at a slightly stretched length and placed 
into glutaraldehyde/paraformaldehyde (2.5%/1%) for electron microscopy (EM). Tissue 
for immunohistochemistry was embedded in optimal cutting temperature medium and 
frozen in isopentane cooled in liquid nitrogen. Tissue was also taken for measurement of 
mechanical properties of skeletal muscle fibers, but those data are not presented. 
Remaining tissue was frozen in liquid nitrogen and stored at -80°C until analysis. In one 
breast cancer patient, sufficient tissue was obtained only for EM analysis. 
  
Immunohistochemistry. Muscle fiber cross-sectional area (CSA) and myonuclear 
number were quantified by immunohistochemistry using rabbit anti-laminin (Abcam) and 
mouse anti-MHC I antibodies (DSHB), as described (11). Nuclei were stained with 4',6-
diamidino-2-phenylindole (Invitrogen). CSA measurements were performed using image 
analysis software (NIH ImageJ, version 1.51n). Although the myonuclei count will 
include muscle satellite cells, these are a small fraction of the nuclei under the laminin 
border (<5%; (46)). For healthy controls, immunohistochemistry was available on 5 
volunteers because of limited tissue. 
 
Myosin heavy chain (MHC) content and isoform distribution. MHC content and 
isoform distribution were measured in tissue homogenates via gel electrophoresis, as 
described (58), as a marker of the relative fiber type distribution of muscle.  
  
Electron microscopy. EM was conducted on intact (i.e., unskinned) skeletal muscle 
fibers to assess intermyofibrillar and sub-sarcolemmal mitochondrial area fraction, 
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average area and number, as estimates of mitochondrial content, and myofibrillar 
fractional area, as described (10).  
 
Cell culture. Cultured murine myotubes were used to evaluate the singular effect of 
chemotherapy agents on skeletal muscle cell biology; primarily, mitochondrial content 
and oxidant production. Use of this system obviates the possible secondary effects of 
these drugs on muscle through effects on other organs/tissue systems (e.g., cardiac 
damage and failure due to doxorubicin administration (26)), which could affect skeletal 
muscle (54)). The C2C12 model has been used to characterize the effects of tumor-
derived factors on mitochondrial oxidant production (39), effects that have been 
confirmed in vivo in pre-clinical models (7).  
 
C2C12 myoblasts (ATCC® CRL-1772™, Manassas, VA) were cultured in low glucose 
(1 g/L), Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS; Gibco™ Thermo Fisher Scientific Waltham, MA) and antibiotics 
(50 U/ml penicillin and 50 μg/ml streptomycin). Cells were plated (1.5 X 104 cells/cm2) 
on Matrigel (40 μg/cm2; Corning, Bedford, MA) and switched to low serum, high glucose 
(4.5 g/L) DMEM (1% heat-inactivated FBS) to induce differentiation, as generally 
described (34). On day 7 post-differentiation, myotubes were treated with doxorubicin 
(DOX), paclitaxel (TAXOL) (both Sigma, St. Louis, MO), cisplatin (CIS; Tocris, 
Minneapolis, MN) or respective vehicle control (DMSO for DOX and TAXOL and PBS 
for CIS) for 3 days. DOX dose was based on prior work (24) and serum concentrations 
(47). TAXOL (66) and CIS (56) doses were based on tumor intracellular levels. In all 
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cases, preliminary dose response studies were undertaken to obtain doses for DOX (0.2 
μM), TAXOL (40 nM) and CIS (10 µM) that elicited loss of myotube myosin content 
over the 3 day study period. In DOX and TAXOL experiments, where increased oxidant 
generation was noted (Figure 5 and 6), MitoQ (MedKoo Biosciences, Morrisville, NC), a 
mitochondrial-targeted anti-oxidant was added concurrent with chemotherapeutics to 
determine whether decreasing mitochondrial oxidant stress prevents atrophy. MitoQ has a 
narrow therapeutic range, a characteristic that we found varied by chemotherapeutic. 
Accordingly, doses were 0.25 μM for DOX and 0.125 μM for TAXOL. On the final day 
of treatment, myotubes were harvested for protein expression via western blot or 
underwent mitochondrial measurements.  
 
No genetic testing was conducted to validate the cell line. However, upon serum 
withdrawal, these cells fuse to form multinucleated cells (Figure 5) and express 
myofilament proteins, such as myosin, actin, and α-actinin (unpublished data). At day 7 
post-differentiation, when chemotherapy treatment began, myotubes contain 
myofilaments, contract with electrical stimulation and demonstrate intracellular calcium 
release and reuptake (unpublished data). All of these anatomic and physiologic 
characteristics have been demonstrated in C2C12 myotubes previously (33, 34, 38). 
Additionally, we found that electrically stimulated contraction could be mitigated by 
blocking either sodium channels with tetrodotoxin or myosin ATPase activity with N-
benzyl-p-toluene sulphonamide, with the former mitigating intracellular calcium currents 
and contractures and the latter only mitigating contractures (unpublished data). Here 
again, these characteristics of the contractile response and its sensitivity to specific 
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pharmacological agents have been demonstrated by others (14, 44). Thus, C2C12 
myotubes demonstrate many classical phenotypes of in vivo skeletal muscle. 
 
Myotube mitochondrial content and reactive oxygen species (ROS) production. 
Mitochondrial content and ROS production were measured with fluorometric dyes, as 
described (45, 64) with minor modifications. C2C12 myotubes grown in black-walled, 
96-well plates were loaded with fluorescent dyes to assess mitochondrial content (1 μM 
MitoTracker Green FM; 490/516 nm) and ROS production (1 μM MitoSOX Red; 
510/580 nm; both Molecular Probes, Eugene, OR) 15 minutes prior to measurement. 
Fluorescence was measured on a microplate reader (BioTek, Winooski, VT). The ROS 
signal (MitoSox) was expressed relative to MitoTracker signal to control for any effect of 
the chemotherapeutic to modify mitochondrial content. MitoTracker Green FM was 
chosen because its labeling of mitochondria is insensitive to membrane potential, as this 
could be affected by chemotherapeutics (23). To confirm co-localization of MitoTracker 
and MitoSox signals in myotubes, myoblasts were plated (2.5 X 104 cells/cm2) on 
Matrigel-coated (60 μg/cm2), 35 mm, glass bottom imaging dishes (MatTek; Ashland, 
MA) and differentiated following procedures described above, with the exception that 
media was changed daily for the first 3 days following the start of differentiation. Cells 
were imaged on a Nikon Ti-E inverted microscope in a heated environmental chamber, 
equipped with a Clara CCD camera (Andor) and Spectra X light engine. 
 
Western blot analysis. Skeletal muscle tissue was homogenized, as described (59), in a 
sub-set of patients (n=9) and controls (n=11), where tissue was available. In a sub-set of 
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breast cancer patients (n=11), mitochondria were isolated, as described (35), and treated 
as below for peroxiredoxin-3 (Prx 3) assessments. Myotubes were washed with 
phosphate buffered saline, lysed (50 mM Tris, 150 mM NaCl, 10% (v/v) glycerol, 0.5% 
IGEPAL CA-630,1 mM EDTA), incubated on ice for 30 min and centrifuged. 
Homogenate, mitochondrial isolate, and lysate protein contents were measured (BioRad 
DC Protein Assay, Hercules, CA) and diluted in gel loading buffer. For Prx 3, tissue 
homogenates and myotube lysates were treated with N-ethylmaleimide (NEM) to prevent 
oxidation and/or dimerization of Prx 3 during processing and then placed in gel loading 
buffer with (reducing) or without DTT (non-reducing). Oxidation of Prx 3 can be used as 
a marker of intracellular oxidative stress (49) and mitochondria specifically, as Prx 3 is 
localized to mitochondria. The importance of Prx 3 in muscle is underscored by studies 
showing that altered expression modulates mitochondrial content, morphology, and 
function, as well as muscle contractility (36). Proteins separated by SDS-PAGE were, 
transferred to nitrocellulose (Prx 3) or polyvinylidene (PVDF; all others), blocked (either 
BSA, non-fat milk in Tris-buffered saline, or Odyssey Blocking buffer) and incubated 
overnight with Prx 3 (1:6000; Cat# LF-PA0030, Thermo Fisher), p38 (1:1000; Cat# 
9112, Cell Signaling), phospho-p38 (Thr 180/Thr 182; 1:500; Cat# 4511, Cell Signaling), 
ERK1/2 (1:1000; Cat# 9102, Cell Signaling), phosoho-ERK1/2 (Thr 202/Thr 204; 1:500; 
Cat# 9106, Cell Signaling), α-tubulin (Cat# 12G10, Developmental Studies Hybridoma 
Bank; 0.5 μg/mL), detyrosinated α-tubulin (1:500; Cat# ab48389, Abcam), myosin fast 
(1:15000; Cat# M4276, Sigma) antibodies or GAPDH (1:5000; Cat# MCA4739, Biorad). 
Blots were washed and incubated with secondary antibodies conjugated to horseradish 
peroxidase and developed by chemiluminescence (Clarity Western ECL Substrate 
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BioRad, Hercules, CA) or the Odyssey Infrared Imaging System (for p38, ERK1/2 and 
tubulin analytes; IRDye 680 or IRDye 800 secondary antibodies; both LiCor, Lincoln, 
NE). Bands were quantified by densitometry (Quantity One; BioRad, Hercules, CA or 
Odyssey Application Software v3.0; LiCor, Lincoln, NE). For analysis that required 
running more than one gel, data were normalized to an internal loading control to permit 
comparisons across gels. Technicians were blinded to group assignment or treatment.  
  
Statistics. Differences between groups were determined using unpaired t-tests. For 
variables with multiple observations within the same individual (e.g., single fiber CSA), a 
linear mixed model was used, including a between-subject effect of group assignment 
(control or cancer) and a repeated effect to account for variation in fiber characteristics 
within each individual. This effect accounts for the fact that each fiber within an 
individual is not independent and has some relationship to other fibers within that 
individual. The mixed model is preferable to taking an average value for each individual, 
which makes the erroneous assumption that within-subject variation is zero. Instead, the 
mixed model considers this within-subject variation in the derivation of within-group 
variance to test for fixed effects (i.e., group differences). Least squared mean and 
variance estimates are used to test for fixed effects in the mixed model. However, 
arithmetic means are displayed figuratively and in the text to correspond with individual 
data (or individual average data for variables with multiple observations per volunteer), 
the latter of which is plotted to illustrate the spread of data. For cell culture experiments, 
unpaired t-tests or one-way analysis of variance were used. Finally, relationships between 
variables were determined by Pearson correlation coefficients, with normality confirmed 
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by Shapiro-Wilk test. For non-normally distributed variables that remained so following 
data transformations (e.g., MHC II CSA), Spearman rank correlation coefficients were 
used. SPSS (version 23, IBM Co., Armonk, NY) was used for all statistical analysis, 
except mixed model analysis (SAS, version 9.4, SAS Institute Inc., Cary, NC). All data 





Disease and physical characteristics. Controls were older, but groups were similar for all 
body size and composition variables (Table 1). Disease and treatment characteristics of 
patients are detailed in Table 1. Five patients reported unintentional weight loss during 6 
months prior to testing (-4.0 ± 1.1 kg; range: 1 to 7 kg), with 3 (1 stage I, 1 stage II and 1 
stage III) reporting >5% loss (-5.7 ± 0.7 kg). Breast cancer patients were studied an 
average of 59 ± 10 d into their chemotherapy regimens (range: 5-114 d).  
 
Single muscle fiber characteristics. Breast cancer patients showed lower single muscle 
fiber CSA compared to controls (P<0.05; n=1682 and 450 fibers; Figure 1A), with lower 
MHC II fiber CSA (P=0.05; n=745 and 228 fibers) and a trend toward lower MHC I CSA 
(P=0.07; n=937 and 222 fibers). No differences in CSA were found between patients 
reporting weight loss and those reporting weight stability in all fibers, or MHC I or II 
fibers separately, (P>0.40; data not shown). Of note, as detailed in the Statistics section, 
statistical tests for group differences are based on the number of volunteers per group, not 
the total number of fibers. No differences were found in myonuclear number per fiber in 
MHC I or II fibers (Figure 1B). Finally, we found no differences between groups for 
myofibrillar fractional area by EM (Figure 1C) or myosin or actin protein in tissue 
homogenates (Figure 1D). 
 
Mitochondrial content and structure. In breast cancer patients, intermyofibrillar 
mitochondria fractional area was lower (P<0.03) than controls (Figure 2A), due to 
smaller (P<0.02) average mitochondrion area (Figure 2B), with no difference in number 
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(control: 0.24 ± 0.03 vs. cancer: 0.29 ± 0.03 n/μm2). Similarly, sub-sarcolemmal 
mitochondrial fractional area was reduced (P<0.05; Figure 2C) due to decreased number 
of mitochondria per unit area (P<0.01; Figure 2D), while average sub-sarcolemmal 
mitochondrion area showed a trend (P=0.07) towards being greater in cancer patients 
(control: 0.95 ± 0.08 vs. cancer: 1.59 ± 0.26 µm2). Sub-sarcolemmal area did not differ 
between groups (control: 21.7 ± 2.3 vs. cancer: 21.7 ± 1.6 µm2). Finally, in the breast 
cancer patients, reduced intermyofibrillar mitochondrial size was associated with smaller 
CSA in both MHC I (r=0.792; P<0.01) and II (r=0.769; P<0.01) fibers, whereas 
intermyofibrillar mitochondrial size was not associated with CSA in either fiber type in 
controls (both P>0.50). Reduced sub-sarcolemma mitochondrial fractional content was 
associated with smaller MHC II CSA in cancer patients (r=0.743; P<0.01), but not 
controls in either fiber type (P>0.60). 
 
We examined whether differences in fiber type distribution, a marker of muscle fiber type 
proportion, might account for variation in mitochondrial parameters. Breast cancer 
patients were characterized by a lower fractional content of MHC I proteins compared to 
controls (35.8 ± 0.8 vs. 39.0 ± 1.2%; P<0.05), although neither MHC IIA (36.3 ± 0.3 vs. 
35.8 ± 1.0%) nor MHC IIX (27.9 ± 0.9 vs. 25.2 ± 1.5%) differed. Variation in MHC I 
fractional content, however, was not associated with mitochondrial fractional content 
from either compartment in the whole group or either group separately. Moreover, as 
slopes of these relationships were shallow (range: -0.005 to 0.064), modest differences in 
MHC I fiber fractional content would likely not explain group differences in 




Prx 3 expression. To examine whether mitochondrial oxidant stress in cancer patients is 
associated with muscle fiber size, we evaluated the expression and oxidation state of the 
mitochondrial-targeted anti-oxidant enzyme Prx 3 in a sub-group of breast cancer patients 
(n=9). We found that expression of Prx 3 was negatively related to both MHC I and 
MHC II CSA (Figure 3A and 3B, respectively). Moreover, in mitochondrial isolates 
(n=11), increased amounts of oxidized Prx 3 in breast cancer patients was related to 
decreased CSA in MHC II fibers (Figure 3C).  
 
To further examine whether chemotherapeutics might contribute to variation in Prx 3 
expression and/or oxidation, we treated C2C12 myotubes for 3 days with DOX or 
TAXOL, two commonly used chemotherapeutics in our population (Table 1). DOX did 
not affect Prx 3 expression, whereas TAXOL reduced Prx 3 expression (Figure 3D; 
n=4/group). Note that the two bands shown under reducing conditions are due to the 
addition of NEM to prevent oxidation and/or dimerization during processing, as samples 
not treated with NEM showed only one band (data not shown). The above results reflect 
quantification of both bands. Under non-reducing conditions, we found that DOX 
increased oxidized Prx 3 in myotubes (P<0.05), as shown by increased Prx 3 dimer 
(Control: 100 ± 8.9 vs. DOX: 162.5 ± 11.0 vs. TAXOL: 106.7 ± 6.1%; Figure 3E). 
Because TAXOL reduced Prx 3 expression (Figure 3D), we calculated the relative 
amount of dimer in each treatment group as a function of monomer + dimer as a marker 
of mitochondrial oxidative stress. This did not alter the results, as oxidized Prx 3 in DOX 




Tubulin expression and detyrosination. Because mitochondrial motility and 
communication occur via kinesin-dependent movement along microtubules, and because 
taxane chemotherapeutics, which were taken by all breast cancer volunteers, alter tubulin 
expression and post-translational modification in skeletal muscle, we examined the 
effects of taxanes on tubulin expression and post-translational modification. In C2C12 
myotubes, treatment with TAXOL (40 nM for 3 days; n=6) increased expression of 
tubulin and detyrosinated tubulin (Figure 4A). Similarly, in patients treated with 
therapeutic doses of taxane chemotherapeutics (n=9), we found increased tubulin and 
detyrosinated tubulin expression compared to controls (n=11; Figure 4B, respectively). 
Because TAXOL can increase ROS production in skeletal muscles, we examined whether 
variation in tubulin or detyrosinated tubulin correlated with mitochondrial content or 
morphology. The average area of intermyofibrillar mitochondria was inversely correlated 
to α-tubulin (r=-0.472; P<0.05) and detyrosinated tubulin (r=-0.580; P<0.01). In sub-
sarcolemmal mitochondria, α-tubulin was negatively correlated to fractional content (r=-
0.558; P<0.05) and number per area (r=-0.654; P>0.01) and positively related to average 
area (r=0.582; P<0.01). 
  
Chemotherapy-induced atrophy and oxidant stress. To further examine the effects of 
chemotherapeutics on skeletal muscle cell size and mitochondrial content and ROS 
production, C2C12 myotubes were treated with DOX, a chemotherapeutic with well-
characterized myotoxicity, or TAXOL, the most common chemotherapeutic in our 
cohort. Treatment with DOX or TAXOL reduced myosin content (Figure 5A; n=15 and 
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9, respectively). That myosin content serves as a proxy of myotube cell size was 
confirmed by the fact that DOX-induced changes in myotube diameter (-22 ± 7% relative 
to controls; n=3 wells/condition) tracked closely with changes in myosin content (-21 ± 
2%; n=10). Accordingly, we utilized myosin protein content as our index of myotube size 
throughout our studies. 
 
Both DOX and TAXOL caused a loss of mitochondrial content (-8 ± 2%, n=16, P<0.01 
and -38 ± 3, n=12, P<0.001, respectively). Accordingly, ROS production, as reflected by 
MitoSox signal, was expressed per unit MitoTracker signal to control for changes in 
mitochondrial content. The use of MitoTracker signal to correct MitoSox signal is based 
on the mitochondrial targeting of both probes, which we confirmed in our preparations 
(Figure 6A). Both chemotherapeutics increased ROS production per unit MitoTracker 
signal (Figure 5B; n=12 and 11, respectively). To examine whether increased ROS 
production with chemotherapeutics contributes to myotube atrophy, we concurrently 
treated cells with the mitochondrial-targeted anti-oxidant MitoQ and observed that it 
prevented DOX- and TAXOL-induced loss of myosin protein content (Figure 5C and D; 
n=12 and 3, respectively). Additionally, MitoQ application to myotubes prevented the 
loss of mitochondrial content (Figure 6B and C; n=12 and 12, respectively) and prevented 
(DOX) or lessened (TAXOL) the increase in ROS production (Figure 6D and E; n=12 
and 12, respectively). 
 
Our prior work showed mitochondrial rarefaction (-50%) in skeletal muscle from patients 
with cancers that are prone to cachexia—primarily lung cancer—where platin-based 
  
109  
drugs were the most common chemotherapeutic (58). To explore whether they have 
effects similar to DOX and TAXOL, we evaluated the effects of CIS on C2C12 
myotubes. CIS caused profound myosin loss (control: 100 ± 17% vs. CIS: 19 ± 4% of 
control; n=3; P<0.01), but did not increase ROS production relative to MitoTracker 
signal (control: 100 ± 1 vs. CIS: 98 ± 1% of control; n=12) and paradoxically increased 
MitoTracker signal (control: 100 ± 6 vs. CIS: 113 ± 5 of control; n=12; P<0.01).  
 
Signaling pathways. Recent studies suggested that upregulation of redox-responsive 
signaling pathways, such as p38 and ERK1/2, may contribute to muscle atrophy with 
chemotherapeutic administration in pre-clinical models. However, we found no 
differences in the expression or phosphorylation of p38 (Figure 6A) or ERK1/2 (Figure 
6B), nor the ratio of phosphorylated to total content of either, between patients (n=9) to 





Breast cancer patients showed evidence of muscle fiber atrophy and mitochondrial 
rarefaction, with reduced muscle fiber size tracking, reduced mitochondrial content and 
increased oxidant stress. Treatment with chemotherapeutics promoted these phenotypes 
in cultured muscle cells, effects that were mitigated by concomitant treatment with a 
mitochondrial-targeted antioxidant. These results provide seminal human data that 
suggest deleterious effects of cancer treatments on muscle secondary to their mitotoxic 
properties. That chemotherapeutics promote these adaptations provides a potential 
explanation for muscle atrophy in cancers not prone to cachexia or early stage patients, as 
well as the high prevalence of fatigue and physical disability across different cancer types 
(12). 
 
Reduced skeletal muscle fiber CSA in breast cancer patients was unlikely due to weight 
loss, as few patients reported weight loss and fiber CSA did not differ between patients 
reporting weight loss and those reporting weight stability. Other groups have reported 
that lean tissue mass is reduced (21), but our report provides evidence of this using direct 
measures of muscle cell size in breast cancer patients. We emphasize this point because 
tissue level imaging-based measurements may not accurately reflect muscle size in 
patients due to effects of treatments on tissue hydration (2). Indeed, we found no 
differences between groups in leg muscle mass by DEXA (Table 1). Such discrepancies 
in humans are not unique to this study, as we (42) and others (4) have shown discordance 
between measures at these different anatomic levels under conditions when tissue 
hydration may be altered (13). Although we acknowledge that biopsy samples represent a 
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small amount of tissue relative to that sampled with imaging techniques, single fiber CSA 
measurements agree well with imaging-based whole muscle CSA under stable 
conditions, where muscle mass and hydration are not changing (11). This potential 
limitation of imaging techniques is noteworthy because most studies to date have used 
these approaches for defining cancer-related muscle atrophy in clinical populations. 
 
This is the first report of skeletal muscle mitochondrial morphological adaptations in 
breast cancer patients, a cohort with a low prevalence of cachexia, and is consistent with 
our results in patients with cancers more prone to cachexia (58), albeit the reduction was 
not as pronounced (current study vs. (58)). While cancer (62) or chemotherapeutics (3) 
may reduce mitochondrial content, the fact that our patients had tumors removed 
surgically and that breast cancer tumors generally do not promote cachexia in pre-clinical 
models (27, 61) suggests chemotherapeutics as a more likely mediator. Indeed, recent 
pre-clinical studies showed that administration of chemotherapeutics used for colorectal 
tumors to mice reduced intermyofibrillar mitochondrial content secondary to decreased 
mitochondrion size (3), a similar morphological phenotype as in our patients. Our results 
also extend both pre-clinical and clinical work (58) to show mitochondrial loss in the sub-
sarcolemmal compartment. Interestingly, different structural characteristics accounted for 
reduced mitochondrial content in sub-sarcolemmal and intermyofibrillar compartments in 
breast cancer patients, suggesting different mechanisms for mitochondrial remodeling in 
the two compartments. Considering the beneficial effect of increasing or maintaining 
mitochondrial content in other models of atrophy (52), therapeutics or interventions (e.g., 
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exercise) that preserve or increase mitochondria may prevent muscle atrophy and 
weakness in cancer patients.  
 
Chemotherapeutics may promote mitochondrial loss through their ability to provoke 
mitochondrial dysfunction and oxidant production, as even modest amounts of oxidant 
stress can promote mitophagy (20). To address this question, we utilized C2C12 
myotubes to examine the singular effect of chemotherapeutics used in breast cancer 
patients on mitochondrial content and oxidant production. We found that 
chemotherapeutics caused mitochondrial loss and increased oxidant production in C2C12 
myotubes. Moreover, treatment with the mitochondrial-targeted antioxidant MitoQ 
prevented a loss of mitochondria, further implicating ROS in mitochondrial loss. In 
contrast, mitochondrial content remained unchanged with CIS, another widely used 
chemotherapeutic that did not increase ROS production. These data provide proof-of-
principle evidence that mitochondrial loss tracks with drug-induced oxidant stress. 
 
Another potential explanation for mitochondrial loss is the effect of taxane 
chemotherapeutics on microtubules, as all of our patients were treated with these drugs. 
Microtubules form a lattice in muscle fibers and serve as tracks to support kinesin-
dependent mitochondrial movement (65) and communication (29). Pre-clinical studies 
show that TAXOL increases the amount of tubulin and its detyrosinated form in skeletal 
muscle (31), which we confirmed in C2C12 murine myotubes. Our results further provide 
seminal data showing that taxanes at therapeutic doses used in human patients upregulate 
tubulin and detyrosinated tubulin levels in skeletal muscle. That taxanes may have 
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detrimental effects on mitochondria in patients is suggested by the negative correlations 
of tubulin and detyrosinated tubulin to mitochondrial content and morphology in both 
compartments. The mechanism whereby TAXOL affects mitochondria is not clear, but 
our data in cultured myotubes and that of others in intact muscle fibers suggests that 
TAXOL increases ROS production (Figure 4B and (32)), which could promote 
mitophagy (20). In support of a role for ROS in promoting mitochondrial rarefaction, we 
found that MitoQ prevented TAXOL-induced mitochondrial loss. Collectively, our 
results highlight novel mitotoxic effects of taxane chemotherapeutics in skeletal muscle. 
 
The effect of chemotherapeutics to increase cellular oxidant stress might also promote 
myofiber atrophy (48). In patients, increased expression and oxidation of Prx 3, which 
our data and that of others (37) from cultured muscle cells suggests may result from 
chemotherapeutics, were associated with reduced CSA in MHC I and II fibers. Moreover, 
in C2C12 myotubes, concomitant treatment with the mitochondrial-targeted anti-oxidant 
MitoQ prevented chemotherapy-induced myosin loss. These findings are not confined to 
cultured muscle cells, as mitochondrial-targeted antioxidants prevent DOX-induced 
atrophy in rodents (43). Our data show that these effects are also apparent in cultured 
muscle cells for TAXOL, the most commonly used drug among our breast cancer 
patients. The mechanisms whereby increased cellular or mitochondrial oxidant stress 
promotes muscle atrophy are not well defined and we found no evidence for activation of 
p38 and ERK in breast cancer patients, signaling pathways that have been suggested to be 
associated with the atrophic effects of chemotherapeutics in pre-clinical models (3). The 
effects of chemotherapy may promote muscle atrophy through other signaling pathways 
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that are sensitive to energetic/oxidative stress created by mitochondrial adaptations, such 
as AMP-activated kinase (63), which can suppress protein synthesis and/or increase 
proteolysis. 
 
Not all chemotherapeutics derive their myotoxic effects through mitochondrial 
adaptations, as we found marked myosin depletion in myotubes with CIS in the absence 
of increased ROS production or mitochondrial rarefaction. The lack of an effect of CIS to 
induce ROS production may be explained by the concentration we used, as prior work 
suggests that mitochondrial effects occur at higher concentrations (5). However, the 
concentrations in our experiments are in line with tumor intracellular levels, and we used 
PBS as a diluent, which yields greater DNA binding capacity and, in turn, cytotoxicity 
(18). Despite the lack of effect on mitochondrial content/ROS production, these data 
nonetheless reinforce the potential myotoxic effects of chemotherapeutics through 
multiple pathways. 
 
Several limitations to our studies deserve note. First, all patients received short courses of 
dexamethasone concurrent with their chemotherapy (1 to 4 days for each cycle, 
depending on symptom severity). Glucocorticoids have well-known effects to cause 
muscle atrophy (53). Whether the short course of dexamethasone given to these patients 
would affect muscle structure or function is not known, but longer-term treatment with 
glucocorticoids combined with bed rest (28 days) lead to only modest changes in muscle 
fiber size (~11% reductions in cross-sectional area; (19)) and chronic treatment has 
minimal effects on mitochondrial content (28). Moreover, the atrophic effects of 
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glucocorticoids are generally more apparent in fast-twitch, MHC II fibers (53), whereas 
we found effects in both fiber types. Thus, we conclude that it is unlikely that 
glucocorticoids alone explain the muscle atrophy or mitochondrial rarefaction that we 
observed in breast cancer patients, but acknowledge that current data is insufficient to 
resolve what effects it might have. Second, because of the cross-sectional nature of our 
study, we cannot discount that muscle phenotypes observed in cancer patients are 
attributable to other factors separate from, or secondary to, cancer and its treatment. For 
example, acute (e.g., following surgical resection) or chronic physical inactivity (40), 
which can also induce muscle atrophy and mitochondrial adaptations, may explain these 
differences. During the review and revision of our manuscript, a study was published 
showing declines in skeletal muscle fiber size and citrate synthase activity over 16 weeks 
in breast cancer patients receiving chemotherapy (41), suggesting that muscle atrophy 
and mitochondrial adaptations occur in concert with cancer treatment. Third, controls 
were slightly older than cancer patients. However, most of the phenotypes noted in 
cancer patients (e.g., fiber atrophy, mitochondrial rarefaction) would worsen with aging, 
suggesting that the age difference likely lessened group differences in these measures. 
Fourth, myotube cultures are not a perfect model of in vivo skeletal muscle. While they 
offer a model system to evaluate the singular effects of select agents and obviate off-
target effects found in vivo (e.g., cardiac damage/failure associated with DOX 
administration (26) could affect skeletal muscle size and function (54)), they do not 
recreate the 3D structural or functional environment of in vivo muscle. Nonetheless, 
numerous aspects of the atrophic process have been studied extensively in myotube 
cultures and been shown to correspond with skeletal muscle in vivo, such as the effects of 
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cancer to promote oxidant stress (7, 39). Fifth, we did not include a group of post-
resection, treatment-naïve patients to further delineate the effects of chemotherapy 
because of practical difficulties in recruiting and studying these patients. Finally, we did 
not standardize for time on chemotherapeutics among patients, although it did not 
correlate with any outcomes that differed between groups. 
 
In summary, our results provide evidence for skeletal muscle atrophy and mitochondrial 
rarefaction in breast cancer patients that may be linked to the mitotoxic effects of 
chemotherapeutics. From a clinical standpoint, these adaptations may contribute to 
muscle weakness (atrophy) and fatigue (mitochondrial). Accordingly, that 
chemotherapeutics have such effects on skeletal muscle provides a possible explanation 
for the high prevalence of fatigue and functional disability across cancer types (12), 
including those not typically characterized by cachexia, such as breast cancer. Given the 
contribution of these side effects to a poor quality of life (8) and increased mortality (6, 9, 
60), interventions designed to counter these effects on muscle may help to alleviate some 
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Figures and tables 
Figure 1. Skeletal muscle fiber cross-sectional area (CSA) in all fibers and myosin heavy 
chain (MHC) I and II fibers (A), myonuclei content in MHC I and II fibers (B), 
myofilament fractional area (C) and MHC and actin protein content in tissue homogenates 
(D) in controls (open bars) and breast cancer patients (gray bars). Data are mean ± SEM, 
with individual data points shown with each bar. For panels A, B and C, multiple 
observations within each individual were averaged to provide a single data point for each 
volunteer. Representative immunohistochemical images used to measure CSA and 
myonuclei content for control and cancer patients are shown above panels A and B, 
respectively. Scale bars=100 µm. Representative electron microscopy images used to 
measure myofilament fractional area (Panel C) for controls and cancer patients are shown 
above panels C and D, respectively. Scale bars=1 µm. AU, arbitrary units. *, P≤0.05; †, 
0.07. 





Figure 2. Skeletal muscle mitochondrial (Mito) content and structure in the 
intermyofibrillar (IMF) and sub-sarcolemmal (SS) compartments. Representative images 
for IMF mitochondrial fractional area for controls and cancer patients are shown above 
panels A and B, respectively, with average IMF mitochondrial fractional area (A) and 
average size (B) for controls (open bars) and breast cancer patients (gray bars). 
Representative images for SS mitochondria for controls and cancer patients are shown 
above panels C and D, respectively, with average SS fractional area (C) and average 
number (n) per unit sub-sarcolemmal area (D). Scale bars= 1 µm for all images. Data are 
mean ± SEM, with individual data points shown with each bar. For panels A-D, multiple 
observations within each individual were averaged to provide a single data point for each 
individual. *, P<0.05 and **, P<0.01 compared to controls. 
Figure 3.0.2: Breast Cancer patient mitochondrial morphology. 
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Figure 3. Relationship of mitochondrial oxidant stress to myofiber size and chemotherapy 
administration. The relationship of MHC I (A) and MHC II (B) CSA to peroxiredoxin 3 
(Prx 3) expression, and MHC II CSA (C) to oxidized Prx 3 in breast cancer patients (black 
squares). The r-value in A is a Pearson coefficient, while r-values in B and C are Spearman 
rank coefficients. For panels A and B (n=9) and C (n=11). Effects of 3 days of doxorubicin 
(DOX; 0.2 µM) or paclitaxel (TAXOL; 40 nM) treatment (gray bars) vs. control (Ctrl; 
DMSO; open bar) on C2C12 myotube Prx 3 expression (D, n=4/condition) and oxidation, 
with the latter being shown by Prx 3 dimers (oxidized) under non-reducing conditions, as 
shown in the blot in panel E. Quantitation of oxidized Prx 3 is shown in F (n=4/condition). 
Data in D and F are mean ± SEM, with individual data points shown with each bar. For 
panels A-C, multiple observations for CSA within each individual were averaged to 
provide a single data point for each individual. For panel D, immunoblots are shown above 
average data with loading control (GAPDH). Loading controls were not shown for panel 
E, as oxidized Prx 3 data are expressed as a fraction of total (oxidized + non-oxidized) Prx 
3. *, P<0.05 compared to control conditions.  
  





Figure 4.  α-tubulin (α-tub) and detyrosinated (deTyr) tubulin expression. α-tubulin and 
detyrosinated tubulin were assessed following 3 days of treatment of C2C12 myotubes (A) 
with vehicle (CTRL; treated with DMSO; clear bars; n=6) or TAXOL (40 nM; gray bars; 
n=6), and in controls (open bars; n=11) and breast cancer patients (gray bars; n=9)(B). Gels 
images are provided for both experiments. Data are mean ± SEM, with individual data 
points shown with each bar. *, P<0.05 and **, P<0.01 compared to controls.  
Figure 3.0.4: Tubulin content in breast 
cancer patients and C2C12. 
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 Figure 5. Chemotherapeutic effects on myotube myosin content. The effects of 3 days of 
DOX (0.2 µM) or TAXOL (40 nM) administration (gray bars) versus vehicle (DMSO in 
both; CTRL; open bars) on myosin content (A) and ROS production (B), with 
representative images of myotubes for each experimental condition in panel A shown 
above (scale bar for all images=100 μm).The effects of concomitant treatment with the 
mitochondrial-targeted anti-oxidant MitoQ (0.25 µM for DOX and 0.125 µM for TAXOL; 
gray bars) to prevent myosin loss with DOX or TAXOL are shown in panels C and D, 
respectively, with representative images of myotubes for each experimental condition 
shown above (scale bar for all images=100 µm). Data are mean ± SEM, with individual 
data points shown with each bar. *, P<0.05 and **, P<0.01 compared to control conditions. 
 
Figure 3.0.5: Mitochondrial anti-oxidant administration 
on myosin content. 
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Figure 6. Effect of chemotherapeutics (gray bars) and concomitant treatment with the 
mitochondrial-targeted anti-oxidant MitoQ (+MitoQ; 0.25 µM for DOX and 0.125 µM for 
TAXOL) on mitochondrial content (B and C, respectively) and oxidant production (D and 
E) vs. vehicle control (DMSO; clear bars). Data are mean ± SEM, with individual data 
points shown with each bar. Co-localization of MitoTracker (green) and MitoSox (red) in 
a C2C12 murine myotube (A). Scale bar=10 μm. *, P<0.05 vs. controls; **, P<0.01 vs. 
controls; #, P<0.01 vs. TAXOL. 
  




Figure 7. p38 (A) and ERK1/2 (B) expression and phosphorylation (pp38 and pERK1/2, 
respectively) in tissue homogenates from controls (open bars; n=11) and breast cancer 
patients (gray bars; n=9). Gels images are provided for both phospho- and total protein, as 
well as GAPDH. The ratio measure reflects the ratio of phospho- to total protein. Data are 
mean ± SEM, with individual data points shown with each bar. 
  
Figure 3.0.7: Patient p38 and ERK content. 
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Table 3.3. Physical and disease characteristics in patients. 
 Control Cancer  
n 12 13 
Age (yr) 66 ± 5  57 ± 12 * 
Body weight (kg) 67 ± 15 70 ± 13  
Height (cm) 164 ± 5 161 ± 8  
Fat mass (kg) 24 ± 12 28 ± 11 
Fat-free mass (kg) 40 ± 5 40 ± 4 
Fat-free mass index 
(kg/m2) 
15.2 ± 1.3 15.4 ± 1.6 
Leg fat-free mass (kg) 13 ± 2 14 ± 2 
Cancer Stage (I/II/III) NA 7 / 2 / 4 
Histology (n) 
   Adenocarcinoma 
 
                 NA 
 
13 
Dexamethasone (n) NA 13 
Chemotherapeutics (n) 
   Taxanes 
 
                 NA 
 
13 
   Cyclophosphamide                  NA 8 
   Doxorubicin NA 5 
   Trastuzumab NA 3 
History of smoking (n) NA 1 
Radiation (n) NA 0 
 




List of abbreviations 
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Muscle contraction may protect against the effects of chemotherapy to cause skeletal 
muscle atrophy and weakness, but the mechanisms underlying these benefits are unclear. 
To address this question, we utilized in vitro modeling of contraction and 
mechanotransduction in C2C12 myotubes treated with doxorubicin (DOX; 0.2 μM for 3 
days). Myotubes expressed contractile proteins and organized these into functional 
myofilaments, as electrical field stimulation (STIM) induced intracellular calcium (Ca2+) 
transients and contractions, both of which were prevented by inhibition of membrane 
depolarization. DOX treatment reduced myotube myosin content, protein synthesis, Akt 
(S308) and forkhead box O3a (FoxO3a; S253) phosphorylation and increased muscle 
ring fiber 1 (MuRF1) expression. STIM (1 h/d) prevented DOX-induced reductions in 
myotube myosin content and Akt and FoxO3a phosphorylation, as well as increases in 
MuRF1 expression, but did not prevent DOX-induced reductions in protein synthesis. 
Inhibition of myosin-actin interaction during STIM prevented contraction and the anti-
atrophic effects of STIM without affecting Ca2+cycling, suggesting the beneficial effect 
of STIM derives from mechanotransductive pathways. Further supporting this 
conclusion, mechanical stretch of myotubes recapitulated the effects of STIM to prevent 
DOX suppression of FoxO3a phosphorylation and upregulation of MuRF1. DOX also 
increased reactive oxygen species (ROS) production, which led to a decrease in 
mitochondrial content. While STIM did not alter DOX-induced ROS production or anti-
oxidant gene expression, PGC-1α expression was induced and mitochondrial loss 
prevented. Our results suggest that the activation of mechanotransductive pathways that 
downregulate proteolysis and preserve mitochondrial content can protect against the 
atrophic effects of chemotherapeutics. 




Cancer afflicts ~1 in 2 men and 1 in 3 women (24). With improved detection and 
treatments, and increased incidence due to an aging populace (51), the number of 
individuals living with effects of cancer and its treatment will exceed 18 million by 2020 
(9) and continue to grow. Cancer and its treatment have profound effects on skeletal 
muscle, including atrophy, impaired contractility and oxidative dysfunction (54, 55, 57), 
that negatively impact quality of life, treatment decisions and survival (4, 6, 10, 41) and 
can persist for years after treatment (35). These detrimental effects reduce quality of life 
and predispose to disability and cardio-metabolic disease.  
Exercise can mitigate the negative effects of cancer and its associated treatment and 
improve long-term prognosis (21, 25, 56). Part of these benefits may derive from the 
positive effect of exercise on skeletal muscle. Exercise induces an array of beneficial 
adaptations in muscle, including improved proteostasis, energy metabolism and 
contractility (3, 13). Although the effects of various exercise regimens have been 
examined in patients (1, 29, 38), the mechanism(s) whereby exercise derives its benefits 
remains unknown. Knowledge of the fundamental mechanisms underlying the benefits of 
exercise could inform the development of more effective regimens that derive the greatest 
benefit with the least burden on patients. Therefore, we utilized in vitro exercise 
modeling in C2C12 myotube cultures subjected to chemotherapeutic treatment, with or 
without electrical field stimulation (STIM), to dissect the mechanisms underlying the 
beneficial effects of exercise on skeletal muscle. We hypothesized that STIM imparts its 
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beneficial effects, in part, via mechanotransductive signaling to upregulate protein 














































Cell culture. C2C12 myoblasts (ATCC® CRL-1772™, Manassas, VA) were cultured in 
growth media (GM), consisting of low glucose (1 g/L), Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Gibco™ Thermo 
Fisher Scientific Waltham, MA) and antibiotics (50 U/ml penicillin and 50 μg/ml 
streptomycin). Cells were plated (2 X 104 cells/cm2) on Matrigel (60 μg/cm2; Corning, 
Bedford, MA) and switched to differentiation medium (DM) of low serum (1% heat-
inactivated FBS), high glucose (4.5 g/L) DMEM when they reached 90-100% 
confluence, as described (36), with modifications as described (18). On day 7 post-
differentiation (d7), myotubes were treated with doxorubicin (DOX) (0.2 μM) or vehicle 
control (DMSO in DM) for 3 d (chronic experiments). Thirty minutes after starting DOX 
treatment, STIM was applied using a C-Pace pulse generator (20V, 1Hz, 12ms; C-Pace 
100, IonOptix, Milton MA) for 1 h each day for 3 days. At the end of each STIM bout, 
myotubes were washed twice with Hank’s buffered salt solution (HBSS), fresh DM 
containing either DOX or vehicle (DMSO) were added and 23 h allowed before the next 
bout of STIM or measurements. In some experiments, myotubes were treated with 
tetrodotoxin (TTX; 10µM), a sodium channel inhibitor, or N-benzyl-p-toluene 
sulphonamide (BTS; 50µM), an inhibitor of myosin-actin ATPase cycling (49), during 
the 1 h STIM bouts. Cells were lysed and collected on d10, 23 h after the last STIM bout, 
to eliminate the possibility that results reflect an acute effect of the STIM intervention. In 
acute experiments, cells were treated with vehicle, DOX alone, STIM or STIM+DOX, as 
described above, to examine acute modulation of protein synthesis, expression of 
proteolytic mediators and signaling molecular phosphorylation, and harvested/measured 
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after 1 or 24 h. In another set of acute experiments, cells were treated with vehicle, DOX, 
cisplatin (CIS; 10 µM) or paclitaxel (TAXOL; 40 nM) without STIM, and harvested after 
24 h. 
A separate set of acute experiments examined the effects of mechanical stretch on C2C12 
myotubes differentiated on type I collagen coated (Advanced Biomatrix, San Diego, CA) 
silastic membranes (GLOSS/GLOSS, 0.02 in, Specialty Manufacturing, Saginaw, MI). 
Silastic membranes were mounted on two friction-fit C-clamps, as previously described 
(14). The screw nuts were set to 30 cycles from baseline when the stretching device was 
assembled, as described (14).  C2C12 myoblasts were suspended (∼1 × 106cells/ml) and 
plated onto silastic membranes (∼1.5–2 × 105 cells/stretching device). The cells were 
grown to ∼95% confluence and differentiated into myotubes using 2% horse serum. 
After 5 days of differentiation, cells were treated with DOX (0.2 μM) or vehicle control 
(DMSO in DM). A 5% stretch was supplied for a duration of 1 h and in cells receiving 
DOX, stretch was started 30 min following the first DOX administration, identical to 
STIM intervention detailed above. Following 1 h, of stretch the membranes were returned 
to baseline, cells washed 2x with HBSS, replaced with the fresh media with or without 




Myotube size. Myotube size was assessed from myotube diameter measurements. Digital 
images of myotube cultures were acquired at 4X magnification. Average diameters (5 
diameters per tube) of n=5 to 25 myotubes per field from n=4 random fields were 
measured using Image J software (NIH, Frederick, MD, USA) by an assessor blinded to 
treatment status. 
 
Immunocytochemistry. Myofilament proteins were visualized by immunocytochemistry. 
Cells were grown on Matrigel-coated (60 μg/cm2), 35 mm, glass bottom imaging dishes 
(MatTek; Ashland, MA) or plastic, as detailed above, with the modification that the 
media was changed daily. Cells were fixed with 4% paraformaldehyde (Fisher Scientific, 
Atlanta, GA), permeabilized with 0.2% Triton-X 100 (Fisher) and blocked with 5% BSA 
in PBS for 1 h at room temperature. Cells were incubated overnight at 4°C in fast skeletal 
muscle myosin antibody (1:500; MY-32; Sigma) followed by secondary antibody (1:100 
anti-mouse IgG, Molecular Probes) to visualize myofilaments, or 1 μM TRITC-
phalloidin (Sigma) to stain actin to visualize the entire cell. Cells were imaged using a 
Nikon Ti-E Inverted Microscope with C2 Confocal at 40X for myofilament measures or 
an Olympus BX51 with Q-Imaging Retiga R6 at 10X. 
 
Measurement of contractility and Ca2+ cycling. Ca2+ transients were recorded from d7-
d10 myotubes grown on Matrigel-coated (60 μg/cm2), 35-mm, glass bottom imaging 
dishes (MatTek; Ashland, MA). For these experiments, cells were plated at a higher 
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density (2.5 X 104 cells/cm2) and DMEM changed daily. C2C12 myotubes were loaded 
with 1 µM Fluo-2-acetoxymethyl ester (Fluo-2 AM, TefLabs, Austin, TX) for 15 min at 
37°C in the dark. Cells were washed once with HBSS and placed in pre-warmed DM for 
10 min. The culture dish was fitted with a custom-built insert that maintained media 
temperature at 37°C and contained platinum electrodes to allow STIM with biphasic 
pulses (20V, 1Hz, 12ms) (Myopacer, IonOptix, Westwood MA). The same experimental 
design used for performing intracellular Ca2+ recordings was applied to contractility 
measurements. Fluorescent signal and cell contractility were traced using an IonOptix 
system, as previously described (58). Ca2+ fluorescence was recorded with an inverted 
fluorescence microscope and galvo-controlled, dichroic mirror filters at 480/510 nm 
(Hyperswitch, IonOptix) (44). Contractions were tracked using the edge detection feature 
of the IonWizard data acquisition software using visible landmarks on/within the 
myotube. Both contraction and Fluo-2 AM fluorescence measurements were made 
simultaneously from the same myotube. Experiments lasted 300 sec. Transient analysis 
was performed using the IonWizard analysis software (IonOptix). For each test condition, 
data for 15-20 seconds of Ca2+ transients or contractions per myotube were averaged, 
using the pacing time as a common reference point, to derive an averaged monotonic 
Ca2+/contractility transient. Fractional change, which indicates the percentage of peak 
following STIM relative to baseline, was used to quantify contractile dynamics and Ca2+ 
transients. Images of the Ca2+ fluorescent signal were acquired (40 frames/sec) using a 
spinning disk confocal microscope (Yokogawa CSU-W1). During these experiments, 




An additional set of experiments were performed without the measurement of Ca2+ 
fluorescence to assess contractility. To aid in the visualization of cell movement, 2 μm 
latex beads (1:1000, L3030; Sigma) were added to the culture dish 2 h prior to STIM. 
Digital video images were collected with a down-sampled field of 512 X 512 pixels2 and 
a frame rate of 10 Hz (MyoCam-S3, IonOptix). Video images were analyzed by first 
establishing a hexagonal grid and tracking each local image featured within each hexagon 
by cross-correlation from frame to frame (Figure 2A, left panel). The displacement of a 
local image relative to its neighboring local images allowed for calculation of local strain 
(i.e., change in relative displacement between neighbors normalized to the original 
distance between neighbors). With each local image having six neighbors, three strains 
oriented at 120° to each other were measured. This orientation of strains allowed for 
calculation of magnitude and orientation of principal strains on a Mohr’s circle similar to 
that based on a delta rosette strain gauge (8). Local strains are depicted as green ellipses 
illustrating the contraction or elongation of the local region (Figure 2A, right panel). 




Myotube mitochondrial content and reactive oxygen species (ROS) production. 
Mitochondrial content and ROS production were measured with fluorometric dyes, as 
described (18). Briefly, C2C12 myotubes grown in 35 mm dishes or black-walled 96 well 
plates were loaded with fluorescent dyes to assess mitochondrial content (1 μM 
MitoTracker Green FM; 490/516 nm) and ROS production (1 μM MitoSOX Red; 
510/580 nm; both Molecular Probes, Eugene, OR) 15 minutes prior to measurement. 
Fluorescence was measured on a microplate reader (BioTek, Winooski, VT) and the 
MitoSox signal was expressed relative to MitoTracker signal to control ROS production 
for variation in mitochondrial content. We have shown that the MitoSox and MitoTracker 
signals co-localize (18).  
 
Protein synthesis. Protein synthesis was measured using the SUnSET technique, as 
described (14). Briefly, 23 h after the last bout of STIM, stretch or control conditions, 1 
μM puromycin (Sigma) was added to myotubes for 30 min prior to lysis and collection. 
Lysates were then analyzed by western blot, as described below. 
 
Protein expression. Protein expression or phosphorylation was measured by western blot. 
Myotubes were washed with phosphate buffered saline, lysed (50 mM Tris, 150 mM 
NaCl, 10% (v/v) glycerol, 0.5% IGEPAL CA-630,1 mM EDTA, containing Protease 
Inhibitor Cocktail (1:100, cat# P8340, sigma) and Phosphatase Inhibitor Cocktail 3 
(1:100, cat# P0044, sigma)), incubated on ice for 30 min and then centrifuged at 14,000 × 
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g at 4 °C for 10 min. Lysate protein contents were measured (BioRad DC Protein Assay, 
Hercules, CA) and diluted in gel loading buffer. Proteins were separated by SDS-PAGE 
(Bio-Rad, Hercules, CA, USA), transferred to polyvinylidene (PVDF) membranes and 
blocked with Tris-buffered saline-Tween buffer (TBST; 150 mM NaCl, 0.05 % Tween-
20, and 20 mM Tris-HCl, pH 7.4) containing 5% non-fatty milk or BSA. After blocking, 
membranes were incubated overnight with primary antibody: anti-puromycin, clone 
12D10 (1:2000, Millipore MABE343, RRID:AB_2566826), myosin (1:20000,Sigma 
M4276, RRID:AB_477190), TRIM63/muscle ring finger 1 (MuRF-1; 1:1000, R&D 
Systems AF5366, RRID:AB_2208833), phospho-p70 S6 kinase (T389; 1A5; 1:1000, 
Cell Signaling Technology 9206, RRID:AB_2285392), p70 S6 kinase (1:1000, Cell 
Signaling Technology 2708, RRID:AB_390722), phospho-AMPK-alpha (T172, 1:2000, 
Cell Signaling Technology 2535, RRID:AB_331250), AMPK (1:2000, Cell Signaling 
Technology 23A3, RRID:AB_490795), phospho-Akt (T308, 1:1000, Cell Signaling 
5056, RRID:AB_10695743), Akt (1:1000, Cell Signaling Technology 4691, 
RRID:AB_915783), phospho-FoxO3a (S413, 1:1000, Cell Signaling Technology 8174, 
RRID:AB_10889562), phospho-FoxO3a (S253, 1:1000, Cell Signaling Technology 
9466, RRID:AB_2106674), FoxO3a ( 1:1000, Cell Signaling Technology 2497, 
RRID:AB_836876). Membranes were washed for 30 min in TBST and then incubated for 
1 h at room temperature in 5% milk-TBST containing secondary antibody. For 




RNA isolation and quantitative real-time PCR (qPCR). Total RNA was isolated from 
C2C12 cells using Trizol reagent followed by a chloroform-isopropanol extraction 
(Invitrogen, USA), and the concentration and quality measured using a NanoDrop 2000 
spectrophotometer (Thermo Fisher, Waltham MA). cDNA was synthesized from 100 ng 
of mRNA using the qScript Supermix reagent kit per manufacturer’s instructions 
(Quantabio, Beverly, MA). Quantitative real-time PCR (qPCR) was performed using 
iTaq™ Universal SYBR® Green Supermix (BioRad, Hercules, CA) on a CFX96 Touch 
system (BioRad, Hercules, CA), with the relative mRNA expression calculated using the 
Ct (2−ΔΔCt) method normalized to GAPDH expression. Primer sequences are provided 
in Table 1. 
 
Statistics. One- or two-way analysis of variance (ANOVA) models were used to examine 
differences between groups. For one-way ANOVA, time, pharmacological inhibitor of 
contraction (e.g., BTS or TTX) or chemotherapy were utilized as between group factors. 
In two-way ANOVA, chemotherapy and STIM/stretch/time were used as between-group 
factors. If an interaction effect was noted, pairwise comparisons (Least Significant 
Difference) were performed to identify the location of group differences. Relationships 
between variables were determined by linear regression analysis. All data were analyzed 
using GraphPad Software (v7; La Jolla, CA) and are presented as mean ± standard error 





Characterization of C2C12 myotubes and STIM. C2C12 myotubes were differentiated 
for 7 days before treatment with chemotherapy and/or STIM was started. Under our 
culture conditions, there was a rapid growth and accumulation of myosin between d5 and 
d7 (Figure 1A and B), followed by myosin content and myotube size reaching a plateau. 
At d7, myotubes express myofilament proteins, such as myosin (Figure 1A and 1C), actin 
(Figure 1A) and α-actinin (data not shown), and organize these proteins into 
myofilaments (Figure 1C). These myofilaments are functional, as are other components 
of the excitation-contraction coupling system, as STIM of d7 myotubes provokes 
intracellular Ca2+ cycling (Figure 1D, 1E and 1F; Supplemental Video 1) and contraction 
(Figure 1E and 1F; Supplemental Video 2). Moreover, calcium release and reuptake were 
synchronized with the electric pulses, and with contraction and relaxation of the myotube 
(Figure 1E), respectively. Finally, the degree of fractional shortening tracked with the 
magnitude of the intracellular Ca2+ transient (Figure 1F).  
Myotube contractility was quantified using two techniques. The first involved manual 
selection and automated tracking of two cellular landmarks on myotubes using the edge 
tracking feature of the IonWizard software. Data from these measurements showed that 
myotubes contracted with a fractional strain of 3.9 ± 2.7% (n=13 myotubes; open circles 
in Figure 2C). These measurements, however, suffer bias from manual selection of 
landmarks and limitations in the precision of edge tracking. To address these limitations, 
we developed a novel pixel tracking image analysis approach (Figure 2A and 2B) that 
minimizes these biases. This approach yielded a slightly lower average fractional strain 
  
148  
of 2.6% ± 1.0 (n=17 myotubes; filled circles in Figure 2C). Each technique has strengths 
and weaknesses, but their results generally agreed. Thus, we calculated an average 
fractional strain from all data, which was 3.2 ± 2.0% (Figure 2C). 
Myotube contraction with STIM was sensitive to modulators of excitation-contraction 
coupling (ECC) and myosin-actin cycling. Application of the Na+ channel blocker TTX, 
which prevents membrane depolarization and all downstream ECC events, eliminated 
myotube intracellular Ca2+ cycling (P<0.05) and contraction (P<0.01; Figure 2D and 
Supplemental Figure 2A). Additionally, application of BTS, an inhibitor of myosin-actin 
interaction/ATPase activity, eliminated contraction (P<0.01) without diminishing Ca2+ 
cycling (Figure 2D and Supplemental Figure 2B).  
 
STIM prevents DOX-induced myosin loss. A DOX by STIM interaction effect (P<0.01) 
was observed for myosin content, such that DOX caused a reduction in myosin content 
(P<0.01), whereas 1 h of STIM each day during DOX administration prevented loss of 
myosin (Figure 3A). STIM alone did not alter myotube myosin content relative to 
control. To confirm that STIM-induced membrane depolarization and subsequent 
intracellular Ca2+ cycling and contraction were required for this protective effect of 
STIM, we treated myotubes with TTX, as this eliminates intracellular Ca2+ cycling and 
contraction (Figure 2D and Supplemental Figure 2A). Treatment with TTX prevented the 




DOX and STIM effects on protein synthesis and proteolytic mediators. To examine the 
mechanism by which STIM prevented DOX-induced myosin loss, we measured acute (1 
d) modulation of protein synthesis and expression of MuRF1, an E3 ubiquitin ligase 
responsible for ubiquitination of myosin (7). DOX treatment reduced protein synthesis 
rate (Figure 3C and 3D; P<0.01 DOX effect) and phosphorylation of p70S6 kinase 
(T389; Figure 3E; P<0.01 DOX effect), and STIM was unable to preserve either protein 
synthesis or p70S6 kinase phosphorylation in DOX-treated cells (Figure 3C, 3D and 3E, 
respectively).  
A DOX by STIM interaction effect was noted for MuRF1 expression (P<0.01), such that 
DOX increased MuRF1 protein (P<0.01) and STIM prevented the DOX-induced increase 
in MuRF1 expression, while STIM alone did not alter MuRF1 (Figure 3F). A DOX by 
STIM interaction was also noted for FoxO3a phosphorylation (S253) (P<0.01), where 
DOX reduced FoxO3a phosphorylation and this reduction was prevented by STIM 
(P<0.01), while STIM alone did not alter FoxO3a phosphorylation (Figure 3G). At this 
same time point (1 d), STIM reduced Akt phosphorylation (S308; Supplemental Figure 
2A, P<0.01 STIM effect), but no DOX or DOX by STIM interaction effects were noted. 
Because regulation of Akt may be transitory (45), we explored Akt phosphorylation early 
following the first STIM bout (1 h; Figure 3H). At this time point, we found a DOX by 
STIM interaction effect (P<0.05). Pairwise comparisons showed that DOX+STIM was 




Effects of other chemotherapeutics on protein synthesis and MuRF1 expression. We 
explored whether other commonly used chemotherapeutics that cause myotube myosin 
loss (18) alter protein synthesis and MuRF1 expression similar to DOX at 1 d post-
treatment. Results showed that both CIS and TAXOL upregulate MuRF1 expression 
(P<0.01 and P<0.05; Figure 4A) and reduce protein synthesis (P<0.01 for both; Figures 
4B and 4C), similar to DOX (P<0.01 for both panels), suggesting a common effect of 
numerous chemotherapeutics on myotube protein metabolism.  
 
Role of contraction and cell stretch in mediating effects of STIM. To examine if 
mechanical contraction and myotube shortening explain the protective effects of STIM, 
we treated myotubes with BTS, an inhibitor of myosin-actin interaction that prevents 
myotube contraction, but does not disrupt intracellular Ca2+ cycling (Figure 2D and 
Supplemental Figure 2B), during 1 h STIM sessions. BTS blocked the effect of STIM to 
prevent DOX-induced myosin loss over 3 d of treatment (Figure 5A; P<0.01 DOX 
effect). To clarify whether the effects of STIM were mediated via mechanotransductive 
signaling, we mechanically stretched cells (5%) for 1 h during DOX or vehicle 
treatments. The magnitude of the stretch stimulus was chosen to match the relative strain 
of myotubes induced by STIM (Figure 2C). DOX by stretch interaction effects were 
found for MuRF1 (P<0.01) and FOXO3a (S253; P<0.05). Pairwise comparisons showed 
that, similar to STIM experiments (Figure 3), DOX stimulated MuRF1expression (Figure 
5B; P<0.01) and reduced FoxO3a phosphorylation (S253; P<0.05; Figure 5C), and 
mechanical stretch prevented these alterations (Figure 5B and 5C). Stretch alone did not 
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alter MuRF1 expression or FoxO3a phosphorylation. In contrast to STIM, however, 
mechanical stretch remediated DOX-induced reductions in protein synthesis (Figures 5D 
and 5E; P<0.01 DOX by stretch interaction). These changes in protein synthesis were 
generally paralleled by altered p70 S6K phosphorylation of (Figure 5F), but the 
interaction effect was not significant (P<0.01 stretch effect and P<0.01 DOX effect).  
 
Activation of TRPV1 with CAP does not mimic effects of STIM on myotube myosin 
content. Recent work identified activation of TRPV1 channels as integral to the muscle 
anabolic response to mechanical stimuli, that the anabolic response to stress was 
mimicked by the TRPV1 agonist CAP and that CAP could prevent the catabolic effects 
of unloading and denervation (26). Because the effects of STIM were dependent on 
myotube contraction (i.e., mechanotransduction; Figures 3B and 5A) and were mimicked 
by cell stretch (Figure 5B and 5C), we reasoned that CAP administration may mimic the 
effects of STIM. Initially, we performed a dose-response experiment to examine the 
effects of CAP (50 nM to 1 µM) for 3 d (d7-d10) on myotube myosin content. To our 
surprise, we found no effect of CAP on myosin content at any concentration. We chose a 
dose of 100 nM CAP because prior work showed that this was sufficient to activate 
anabolic pathways (e.g., p70S6 kinase; (26)). CAP (100 nM) did not mitigate the effect of 
DOX administration to reduce myotube myosin protein content (Figure 6B). To further 
interrogate whether a higher dose of CAP could mimic mechanotransductive signaling 
and protect against DOX-induced atrophy, we also treated cells with 1 μM CAP. 
However, this higher dose of CAP similarly did not mitigate the effects of DOX to reduce 
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myosin content (Figure 6C). Finally, 100 nM CAP showed a DOX by CAP interaction 
effect (P<0.01) on ROS production, but not with directionality that would be expected to 
mitigate myotube myosin loss. DOX increased ROS production (P<0.01), with an 
additive effect when combined with CAP (Supplemental Figure 3A). We found an effect 
of DOX (P<0.01) to reduce mitochondrial content regardless of CAP treatment 
(Supplemental Figure 3B). 
 
Myotube mitochondrial ROS production, content and antioxidant gene expression. As 
the TRPV1 agonist CAP did not mitigate the effects of DOX, we sought other potential 
mechanisms underlying the protective effects of STIM on myotube myosin content. We 
recently showed that DOX treatment for 3 d increased myotube mitochondrial ROS 
production and reduced mitochondrial content, and that mitochondrial targeted anti-
oxidant treatment prevented DOX-induced ROS production, mitochondrial loss and 
reductions in myotube myosin content (18). As exercise modulates mitochondrial biology 
and redox balance, we examined the effects of STIM on DOX-induced changes in 
mitochondrial content, ROS production, and antioxidant gene expression. One day of 
DOX treatment increased ROS production, and these effects were maintained after 3 d of 
DOX treatment (Figure 7A; P<0.01 DOX effect). Unlike ROS production, 1 d of DOX 
treatment did not reduce mitochondrial content, whereas a reduction (P<0.01) was 
apparent after 3 d of DOX treatment (Figure 7B; P<0.01 DOX by time interaction; 3d 
Control vs. 3 d DOX; P<0.05).  
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A STIM by DOX interaction effect was found on ROS production (P<0.01), such that 
STIM did not prevent DOX-induced upregulation of ROS production at 3 d (Figure 7C). 
In fact, both STIM groups showed increased ROS production at 3 d compared to non-
STIM groups (P<0.01; Figure 7C). DOX alone also increased ROS production (P<0.01). 
A STIM by DOX interaction was noted for mitochondrial content (P<0.05), as STIM 
prevented DOX-induced reductions in mitochondrial content (Figure 7D). This effect of 
STIM to preserve mitochondrial content was accompanied by increased expression of 
PGC-1α (P<0.05 STIM effect; Figure 7E), although no effect of STIM was noted on 
TFAM expression. DOX upregulated TFAM expression (P<0.01 DOX effect).   
Energetic insufficiency brought about by DOX-induced mitochondrial loss could 
contribute to myosin loss via upregulation of AMPK and activation of FoxO3a/MuRF1 
(43). In this context, the protective effects of STIM could derive from its ability to 
maintain mitochondrial content (Figure 7D). To explore this possibility, we evaluated 
AMPK (T172) and FoxO3a (S413) phosphorylation 1 h and 1 d following the start of 
treatments. We found no DOX or DOX by STIM interaction effects on AMPK 
phosphorylation after 1 h (1.5 h post-DOX/1 h post STIM; Supplemental Figure 4A), but 
there was a STIM effect (P<0.05) 1 d following the start of treatments (Figure 7F). Thus, 
the pattern of AMPK phosphorylation did not match the pattern of changes in 
mitochondrial content (Figure 7D) or MuRF1 expression (Figure 3F). Interestingly, 
however, we found that FoxO3a phosphorylation at S413, a site phosphorylated by 
AMPK (17), 1 d following the start of treatments showed a strong trend (P=0.06) towards 
a DOX by STIM interaction effect. Pairwise comparisons showed that there was an 
increase (P<0.05) in FoxO3a phosphorylation with DOX and that STIM prevented this 
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increase. To further examine mechanosensitive control of FoxO3a, we examined the 
effect of mechanical stretch on this phosphorylation site at 1 d post-treatment and found a 
DOX by stretch interaction effect (P<0.05; Figure 7H). DOX increased FoxO3a 
phosphorylation relative to control and stretch control (P<0.01 and P<0.05, respectively). 
However, stretch did not fully remediate the increase in FoxO3a phosphorylation. In fact, 
FoxO3a phosphorylation was increased in the DOX + Stretch group compared to control 
(P<0.05). 
Finally, we examined whether STIM upregulated antioxidant gene expression, as recent 
studies have suggested this possibility (22), and because we previously showed that 
mitochondrial targeted anti-oxidant prevents myotube myosin loss with DOX 
administration (18). DOX (P<0.05) and STIM (P<0.01) effects were found for expression 
of the redox-sensitive transcription factor Nrf2, while no effects were observed for 
KEAP1 (Figure 8A). DOX effects were observed for a number of antioxidant genes, 
including SOD1, SOD2, CAT and GCLM (all P<0.01). DOX by STIM interaction effects 
(both P<0.05) were found for GCLC and GPx1. In the former, DOX increased GCLC 
expression relative to all other groups (P<0.05 to P<0.01). In the latter, DOX increased 
GPx1 expression relative to all other groups (P<0.05). There were no effects of STIM 





How muscle contraction protects skeletal muscle against the detrimental effects of 
chemotherapeutics (33, 40, 52, 53) is unclear. Using in vitro muscle contraction models, 
we show that the atrophic effects of DOX can be prevented by daily bouts of electrically-
induced contraction. STIM prevented DOX-induced downregulation of Akt and FoxO3a 
phosphorylation and increased MuRF1 expression, but was unable to recover protein 
synthesis. STIM effects were mediated via mechanotransductive signaling, as 
pharmacological inhibition of myosin-actin interaction/ATPase abolished these effects 
and mechanical stretch mimicked the effects of STIM. Finally, STIM upregulated PGC-
1α and prevented the loss of mitochondrial content. Our findings suggest that muscle 
contraction counters the catabolic effects of chemotherapy through effects to 
downregulate proteolysis and preserve mitochondrial content via mechanotransductive 
signaling pathways.    
Contrary to our original hypothesis, the most likely mechanism to explain the beneficial 
effects of STIM is reductions in proteolysis, as STIM downregulated DOX-induced 
increases in MuRF1 expression, while protein synthesis was not rescued. How STIM 
modulates MuRF1 expression is suggested by Akt and FoxO3a phosphorylation data. 
Prior studies show that muscle stretch and contraction upregulate Akt activation (45), and 
our data advance these results to show that STIM-induced myotube contraction counters 
the effects of catabolic mediators, such as DOX, to reduce Akt phosphorylation. FoxO3a 
transcriptional effectiveness is regulated, in part, by its cytoplasmic-nuclear localization, 
which is regulated via targeted phosphorylation, particularly by Akt (48). 
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Correspondingly, increased Akt phosphorylation with STIM was associated with similar 
preservation of FoxO3a phosphorylation on the Akt site (S253). The effects of STIM to 
prevent DOX-induced increases in MuRF1 further suggest that these signaling events 
likely reduced FoxO3a transcriptional activity. Supporting the relevance of our results for 
in vivo skeletal muscle are data showing that electrical stimulation of skeletal muscle 
prevents disuse-induced atrophy, in part, via downregulation of MuRF1 expression (11).  
One strength of our in vitro contraction model is that it allows us to discern whether 
STIM mediates these effects via mechano- or Ca2+ chemotransductive signaling 
pathways. BTS application during 1 h daily STIM bouts prevented the ability of STIM to 
preserve myotube myosin content in the face of DOX, implicating mechanotransductive 
pathways in the beneficial effects of STIM. This notion was reinforced by our results 
from mechanical stretch experiments, which showed similar upregulation of FoxO3a 
phosphorylation and decreased MuRF1 expression. These findings concur with studies 
showing that muscle stretch upregulates Akt (2) and reduces nuclear FoxO content and 
DNA binding (39). Such a mechanism may be operative in vivo, as recent studies show 
that muscle stretch diminished atrophy associated with and experimental intensive care 
unit stay via downregulation of MuRF1 expression, whereas it did not alter protein 
synthesis (42). Collectively, these data extend the role of muscle mechanotransductive 
signaling to include protection against catabolic stimuli, and suggest that this occurs 
through suppression of proteolysis, rather than preservation or upregulation of protein 
synthesis (59).   
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Building on this last point, although we attempted to match mechanical stretch to STIM 
by utilizing a similar relative strain, the two stimuli differed with respect to their effects 
on protein synthesis. Unlike STIM, stretch prevented the DOX-induced reduction in 
protein synthesis. The more pronounced effects of stretch on myotube protein synthesis 
may relate to the fact that the mechanical stretch stimulus (5%) was slightly higher than 
the fractional strain during STIM (~3%), as the stretch device has not been validated 
below 5%, while the response to ≥5% has been previously established.  Additionally, 
STIM imparts its mechanotransductive effects through shortening of the cell while stretch 
is an elongation stimulus. More specifically, STIM produces stress/strain on myotubes 
primarily via shortening along their longitudinal axis (Supplemental Video 1), in-line 
with the orientation of myofilaments (Figure 1C). In contrast, the uniaxial mechanical 
stretch model we employed would cause multi-axial lengthening and, in turn, 
stress/strain, because myotubes grow in random orientations relative to the axis of stretch. 
This may explain differences between the two stimuli, as transverse stretch is more 
anabolic than uniaxial stretch (23, 34). Extrapolating from these results, one might 
hypothesize that a more intense mechanical stimulus than that provided by STIM may 
more effectively counter the deleterious effects of DOX by also preserving protein 
synthesis (59). Regardless of differences between STIM and stretch conditions on protein 
synthesis, the similarity in their ability to prevent DOX-induced modifications in 
Akt/FoxO3a/MuRF1 signaling underscores the importance of exercise-induced 




Numerous mechanotransductive-signaling pathways could mediate the effects of 
STIM/stretch. We chose to examine the effect of TRPV1 antagonism with CAP because a 
recent report suggested that activation of TRPV1 with CAP promoted muscle anabolism 
and was sufficient to prevent unloading- and denervation-induced atrophy (26, 27). 
Moreover, activation of TRPV1 channels by CAP increases mitochondrial content and 
function in C2C12 myotubes and mouse muscle in vivo (37). However, we found that 
treatment of myotubes with CAP did not prevent DOX-induced atrophy, nor did it 
counter DOX-induced oxidant production or mitochondrial loss. Although we used a 
concentration of CAP (100 nM) shown to promote muscle anabolism/anti-catabolism (26, 
27) and mitochondrial adaptations (37), higher concentrations (1 µM) similarly failed to 
prevent DOX-induced myosin loss. In fact, we found no evidence for effects of CAP on 
myotube myosin content throughout a range of doses. Thus, our results do not support the 
contention that the beneficial effects of STIM in our model are mediated via 
mechanotransductive signaling through activation of TRPV1 channels via CAP.  
In light of the role for mitochondrial oxidant production and/or rarefaction in the 
deleterious effects of DOX and the protective effects of reducing oxidant stress (18), we 
examined whether the effects of STIM are explained by effects on mitochondrial 
health/redox balance. STIM preserved mitochondrial content, an effect accompanied by 
increased PGC-1α expression, a key mediator of mitochondrial biogenesis that is 
upregulated in response to muscle contraction and that protects against disuse-induced 
mitochondrial loss and atrophy (32, 47). In keeping with studies overexpressing PGC-1α 
(5, 31), STIM may prevent DOX-induced atrophy, in part, through effects on 
mitochondrial dynamics to maintain mitochondria content and/or function. Energetic 
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insufficiency brought about by mitochondrial loss would be expected to upregulate 
AMPK, which can phosphorylate FoxO3a (17), leading to transcription of MuRF1. 
However, the pattern of AMPK phosphorylation (T172) did not mirror the effects of 
DOX or STIM on Akt/FoxO3a/MuRF1 activation/expression. Despite this, FoxO3a 
phosphorylation on S413, which is regulated by AMPK, was increased by DOX and 
reduced to control levels by STIM. In the absence of concordance between AMPK and 
FoxO3a phosphorylation, we posit that STIM-induced upregulation of PGC-1α may 
contribute to inhibition of FoxO3a S413 phosphorylation and MuRF1 expression (20, 43, 
47) and, in turn, myotube myosin loss. 
As prior work from our lab and others suggest that improved redox balance prevents the 
deleterious effects of DOX (15, 16, 18), the beneficial effects of STIM could also be 
explained, in part, by its ability to reduce ROS production and/or increase anti-oxidant 
capacity. Contrary to the former possibility, however, STIM did not diminish the DOX-
induced increase in mitochondrial ROS production. In fact, in keeping with prior work 
(46), STIM-induced myotube contraction increased ROS production (Figure 6C), which 
may partially account for the effects of STIM to upregulate Akt (19) and PGC-1α (50). 
Additionally, contrary to recent reports (22), our results showed that no effect on 
antioxidant gene expression. This may be explained by our milder STIM protocol. In our 
model, ROS production was increased ~20% over baseline (Figure 7C), whereas, in 
Horie et al. (22), STIM increased ROS production ~100% over baseline. Whether 
variation in the magnitude of STIM-induced ROS production explains differences in 
antioxidant gene expression, however, is unclear, as DOX alone increased antioxidant 
gene expression with a similar, or slightly smaller, increase in ROS production compared 
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to STIM alone. There were also differences in the timing of STIM between studies. We 
utilized 1 h of STIM, whereas Horie et al. observed an upregulation of antioxidant genes 
only after 4 h of STIM. Regardless of the explanation for differences between studies, our 
results suggest that the protective effects of STIM are likely not mediated via either 
reduced oxidant production or upregulation of antioxidant defenses. 
Several limitations of our study should be acknowledged. First, responses in myotube 
cultures to STIM and DOX may not emulate skeletal muscle in vivo. However, myotubes 
expressed functional myofilaments, contracted in response to STIM and were sensitive to 
pharmacological inhibitors of ECC and myosin-actin interaction/myosin ATPase similar 
to in vivo muscle. Moreover, adaptations in protein metabolism and signaling were 
similar to those demonstrated in vivo in response to DOX and exercise (33), and these 
patterns mimicked those in other atrophy models (42) and with the use of electrical 
stimulation to protect against atrophy in vivo (11, 12). Thus, while this model has 
limitations, it is likely sufficient to study the metabolic and signaling pathways whereby 
muscle contraction prevents the deleterious effects of chemotherapeutics. Second, static 
mechanical stretch may provoke different cellular responses than the cyclical contracting 
myotubes with STIM (28). However, similar results to prevent upregulation of 
proteolytic signals via FoxO/MuRF1 were found in both models, implicating 
mechanotransductive signaling in the beneficial effects of STIM.  
In summary, the beneficial effects of mechanotransductive signaling in C2C12 myotubes 
can prevent DOX-induced activation of the FoxO-MuRF1 pathway via downregulation of 
Akt activation. These effects of STIM may be mediated, in part, via upregulation of 
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PGC-1α expression, which has been shown to inhibit FoxO3a-induced expression of 
MuRF1 (47) and upregulates mitochondrial content. These effects of STIM parallel the 
benefits of neuromuscular electrical stimulation (NMES) in humans to prevent atrophy 
(12). NMES maintains or improves muscle size and strength in clinical populations (30), 
and might be a useful exercise modality in cancer patients during chemotherapy, as they 
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Figure 4.0.1: Myotube morphology and dynamics. 
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Figure 1. C2C12 murine myotube morphology, protein expression, Ca2+ cycling and 
contraction. (A) Content and morphology of myotubes at d3, d5, d7, d8.5 and d10 are 
shown (scale bar=25 µm; top panels) and following fixation and staining of actin with 
TRITC-labeled phalloidin (scale bar=200 µm; middle panels), with corresponding 
representative gel bands for fast myosin expression at each time point (bottom panel). (B) 
Average myotube myosin (open triangles) expression and diameters (open circles) are 
shown for d3 (n=9 and 107), d5 (n=9 and 116), d7 (n=9 and 177), d8.5 (n=9 and 186) and 
d10 (n=9 and 146, respectively). Differences between days are denoted with different 
letters (all differences are P<0.01 using one-way ANOVA). (C) Myofilament formation in 
d7 myotube using anti-fast myosin antibody (green) in d7 myotubes (scale bar=25 µm). 
(D) Pseudo colored images of intracellular Ca2+ cycling in d7 myotube measured by Fluo-
2 AM in response to 20V, 12 ms pulses at 1Hz. Time signatures for each image are 
provided at the bottom of each panel (frame rate=40/s, scale bar=10 µm). The time 
sequence starts in the upper left corner image, runs from right to left, ending in the bottom 
right image. (E) Raw Fluo-2 AM fluorescence signal, showing intracellular Ca2+ release 
(+ excursion) and reuptake (- excursion; top panels), and contractions (- excursion) and 
relaxations (+ excursion; bottom panels) for several excitation-contraction cycles (left side) 
and the average of 15 contraction cycles (right side) in response to 20V, 12 ms pulses at 
1Hz. (F) Relationship between the relative magnitude of intracellular Ca2+ cycling and 





Figure 4.0.2: Myotube contractile dynamics and intracellular Ca2+ cycling. 
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Figure 2. Contractile dynamics and intracellular Ca2+ cycling in d7-d10 C2C12 myotubes. 
(A) Digital images of C2C12 myotube at rest with hexagonal grid overlay (scale bar=10 
µm; left panel). A blowup of the circled hexagon is provided for baseline (Frame 0) and 
during the peak of contraction (Frame 17) to illustrate contraction monitoring by pixel 
tracking (right panel). Yellow colored ellipses show trackable image contrast, with green 
ellipses tracking local pixel strains and negative displacements signifying contractions. (B) 
Negative displacements of one hexagonal grid showing several contraction cycles. (C) 
Fractional strain of n=30 myotubes measured with edge tracking of manually selected 
myotube features/landmarks (open circles) and pixel tracking approach described above 
and in the Methods section (closed circles). Data are mean ± SEM, with individual data 
points shown. (D) Average fractional change (Δ) in contraction and intracellular Ca2+ 
cycling under basal conditions (n=14 and 17, respectively), following TTX (n=8 and 7, 
respectively) and BTS administration (n=5 and 9, respectively). *, P<0.05 and **, P<0.01 





Figure 4 0.3: STIM molecular changes. 
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Figure 3. Effects of doxorubicin (DOX; 0.2 µM; gray bars) or vehicle (DMSO; CTRL; 
open bars) administration, with or without electrical field stimulation (±STIM; 20V, 12 ms 
pulses at 1Hz for 1 hr/d), on myotube myosin content, protein synthesis, markers of 
proteolysis and signaling molecule expression/phosphorylation. (A) DOX administration 
(3 d) reduces myosin content and STIM prevents this reduction (n=12/bar; P<0.01 DOX 
by STIM interaction). (B) Application of tetrodotoxin (TTX; 10µM) during 1 h STIM bouts 
mitigates its protective effects on myotube myosin content (n=6/bar; P<0.01 DOX effect). 
(C) Representative gel image of protein synthesis measurements using incorporation of 
puromycin into protein, as described in Methods section, for a sub-set of replicates in 1 d 
DOX/STIM experiments. (D) DOX administration (1 d) reduces myotube protein synthesis 
and STIM fails to prevent this reduction (n=6/bar; P<0.01 DOX effect and P<0.05 STIM 
effect). (E) DOX administration (1 d) reduces phosphorylation of p70 S6 kinase (p-p70S6k; 
S308) and STIM fails to prevent this reduction (n=6/bar; P<0.01 DOX effect). (F) DOX 
administration (1 d) increases MuRF1 expression and STIM prevents this increase 
(n=6/bar; P<0.01 DOX by STIM interaction). (G) DOX administration (1 d) decreased 
FoxO3a phosphorylation (p-FoxO3a; S253) and STIM prevents this decrease (n=6/bar; 
P<0.01 DOX by STIM interaction). (H) Phosphorylation of Akt (S308) was higher in STIM 
+ DOX compared to all groups (P<0.05), except DOX, where P<0.01 (n=6/bar; P<0.05 
DOX by STIM interaction). Representative gel images are shown at the top of panels A, 
B, E, F, G and H for a subset of replicates. All data are mean ± SEM, with individual data 
points shown with each bar. *, P<0.05 and **, P<0.01 in figures to denote either DOX 
effects (panels B, D and E) or DOX by STIM interaction effects with a single group 




Figure 4. Effects of 1 d of administration of common chemotherapeutics: doxorubicin 
(DOX), cisplatin (CIS) and paclitaxel (TAXOL), or vehicle (DMSO; CTRL; open bars) on 
MuRF1 expression and protein synthesis. (A) All chemotherapeutics increased MuRF1 
expression (n=6/bar). (B) Representative gel image of protein synthesis measurements 
using incorporation of puromycin into protein, as described in Methods section, for a sub-
set of replicates with chemotherapy administration. (B) Administration of all 
chemotherapeutics reduced myotube protein synthesis (n=6/bar). All data are mean ± SEM, 
with individual data points shown with each bar. *, P<0.05 and **, P<0.01 compared to 
control conditions via one-way ANOVA. 
  




Figure 4.0.5: Stretch molecular changes. 
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Figure 5. Effects of doxorubicin (DOX; 0.2 µM; gray bars) or vehicle (DMSO; CTRL; 
open bars) administration, with or without electrical field stimulation (±STIM; 20V, 12 ms 
pulses at 1Hz for 1 h/d) and application of pharmacological inhibitor of myosin-actin 
contraction/ATPase (1 h/d during STIM), or mechanical stretch (±Stretch; 5% for 1 h/d), 
on myotube myosin content, protein synthesis and markers of proteolysis. (A) Application 
of N-benzyl-p-toluene sulphonamide (BTS; 50µM) during STIM bouts over 3 d of DOX 
administration mitigates the protective effects of STIM on myotube myosin content 
(n=6/bar; P<0.01 DOX effect). (B) Application of 5% stretch prevents increases in MuRF1 
expression (n=6/bar, except DOX, where n=7 for all stretch experiments; P<0.01 DOX by 
Stretch interaction) and (C) reductions in phosphorylation of FoxO3a (S253; P<0.05 DOX 
by Stretch interaction) associated with 1 d of DOX administration. For panel C, DOX was 
lower than all other groups (P<0.05) and DOX+Stretch was higher than all groups at 
P<0.05, except DOX, where P<0.01. (D) Representative gel image of protein synthesis 
measurements using incorporation of puromycin into protein, as described in Methods 
section, for a sub-set of replicates with 1 d DOX administration with or without 5% 
mechanical stretch for 1 h. (E) DOX administration reduces protein synthesis (P<0.01 
DOX by Stretch interaction). (F) For phosphorylation of p70 S6 kinase (p-p70S6k; T308), 
DOX (P<0.01) and Stretch (P<0.01) effects were significant, but not DOX by Stretch 
interaction effect. Data are mean ± SEM, with individual data points shown with each bar. 
*, P<0.05 and **, P<0.01 for DOX (panel A) or DOX by Stretch interaction effects (panels 






Figure 4.0.6: Capsaicin effects on myosin content. 
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Figure 6.  Effects of capsaicin (CAP) or doxorubicin (DOX; 0.2 µM) administration, with 
or without capsaicin administration (CAP), on myotube myosin content. (A) Dose-
response effects of 3 d of CAP administration (50nM, 100nM, 250nM, 500nM, 1µM) vs. 
DMSO vehicle CTRL on myotube myosin content (n=3/bar; one-way ANOVA). (B) 
Treatment with CAP (100 nM) was unable to prevent the effect of 3 d of DOX 
administration to reduce myotube myosin protein content (n=6/bar; P<0.01 DOX effect; 
two-way ANOVA). (C) Similar results were found with administration of high 
concentration CAP (1 μM) (n=6/bar, except control bars, which are n=3/bar; P<0.01 DOX 
effect; two-way ANOVA). Representative gel images are shown at the top of panels A, B 
and C for a sub-set of replicates. Note that the representative gel at the top of the panel for 
a sub-set of replicates was run on a 7.5% gel, which caused separation of myosin isoforms. 
Both bands were quantified. Data are mean ± SEM, with individual data points shown with 






Figure 4.0.7: STIM induced mitochondrial changes. 
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Figure 7. Effects of doxorubicin (DOX; 0.2 µM; gray bars) or vehicle (DMSO; open bars) 
administration, with or without electrical field stimulation (±STIM; 20V, 12 ms pulses at 
1Hz for 1 h/d) or a 5% static stretch, on mitochondrial reactive oxygen species (ROS) 
production, mitochondrial content and anti-oxidant gene expression. (A) 1 and 3 d of DOX 
administration increases myotube mitochondrial ROS production per unit mitochondria 
measured with MitoSox and MitoTracker fluorescent dyes, respectively (n=12/bar; P<0.01 
DOX effect). (B) 3 d of DOX administration, but not 1 d, reduces myotube mitochondrial 
content measured by MitoTracker fluorescent dye (n=22/bar; P<0.05 DOX by time 
interaction). (C) DOX (P<0.01) and STIM (both STIM and DOX+STIM; P<0.01) 
increased mitochondrial ROS production during 3 d of DOX administration relative to 
controls (n=6/bar; P<0.01 DOX by STIM interaction). (D) STIM prevented DOX-induced 
mitochondrial loss (n=6/bar; P<0.05 DOX by STIM interaction). (E) 3 d of STIM 
upregulated PGC-1α alone and with DOX treatment (P<0.05 STIM effect), whereas DOX 
increased TFAM (n=6/bar; P<0.01 DOX effect). (F) No DOX by STIM interaction for 1 d 
but a STIM effect (P<0.05) was noted on phosphorylation of AMPK (p-AMPK; T172; 
n=9/bar). (G) DOX administration (1 d) increases FoxO3a phosphorylation (p-FoxO3a; 
S413; P<0.05) and STIM prevents this increase (n=6/bar; P=0.06 DOX by STIM 
interaction). (H) DOX administration (1 d) increases FoxO3a phosphorylation (p-FoxO3a; 
S413; P<0.06 DOX by STIM interaction; P<0.05 DOX higher than all other groups). (H) 
DOX increased FoxO3a phosphorylation (S413; P<0.05) and mechanical stretch was 
unable to fully reduce this increase (n=6/bar, except DOX, where n=7; P<0.05 DOX by 
Stretch interaction). Data are mean ± SEM, with individual data points shown with each 
bar. *, P<0.05; ** and P<0.01 for DOX or DOX by time/STIM/Stretch interaction effects, 




Figure 4.0.8: Antioxidant enzyme expression. 
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Figure 8. Effects of doxorubicin (DOX; 0.2 µM; gray bars) or vehicle (DMSO; open bars) 
administration, with or without electrical field stimulation (STIM; 20V, 12 ms pulses at 
1Hz for 1 h/d), on anti-oxidant gene expression. (A) 3 d STIM and DOX both increased 
Nrf2 expression (n=6/bar; P<0.05 DOX effect and P<0.01 STIM effect), but had no effect 
on KEAP1 (n=3/bar). (B) DOX increased SOD1, SOD2 and CAT expression, independent 
of STIM (n=6/bar; P<0.01 DOX effect). (C) DOX upregulated GCLM, independent of 
STIM (P<0.01 DOX effect) and DOX alone upregulated GCLC and GPx1 (P<0.05 DOX 
by STIM interaction) (n=6/bar). Data are mean ± SEM, with individual data points shown 
with each bar. *, P<0.05 and ** P<0.01 for DOX or DOX by STIM interactions, with 




Table 4.4: Primer sequences for gene expression analysis. 
Gene Forward 5' to 3' Reverse 5' to 3' 
Cat CGAGGGTCACGAACTGTGTC GGTCACCCACGATATCACCA
Gclc ATCTGCAAAGGCGGCAAC ACTCCTCTGCAGCTGGCTC 
Gclm AGTTGGAGCAGCTGTATCAG TTTAGCAAAGGCAGTCAAA
Gpx1 CCTCAAGTACGTCCGACCTG CAATGTCGTTGCGGCACACC 










GAPDH ACGACCCCTTCATTGACCTC TTCACACCCATCACAAACAT 
 
Cat, catalase; Gclc, glutamate cysteine ligase catalytic subunit; Gclm, glutamate cysteine 
ligase modulating subunit; Gpx1, glutathione peroxidase; Sod1/Sod2, superoxide 
dismutase 1/2; Ppargc1a, peroxisome proliferator-activated receptor gamma coactivator 1-
alpha; Tfam, transcription factor A mitochondrial; Keap1, kelch-like ECH-associated 
protein; Nfe2l2, nuclear factor erythroid 2 like 2; GAPDH, glyceraldehyde phosphate 




Supplemental Figure 1. (A) Raw tracings of Fluo-2 AM-derived intracellular Ca2+ 
cycling (top portion of panel) and contractions (bottom portion of panel) of myotube during 
20V, 12 ms STIM at 1Hz and its response to tetrodotoxin (TTX; 10µM; red dotted line), 
showing cessation of all Ca2+ cycling and contraction. Note that random spikes of 
contractile activity of the myotube upon application and following TTX are due to debris 
floating through the field where cellular landmarks were chosen to track contractile 
activity. These are most prevalent upon initial application of TTX due to fluid shear effects. 
(B) Raw tracings of Fluo-2 AM-derived intracellular Ca2+ cycling (top portion of panel) 
and contractions (bottom portion of panel) of myotube during 20V, 12 ms STIM at 1Hz 
and its response to N-benzyl-p-toluene sulphonamide (BTS; 50µM; 1st red dotted line), 
followed by tetrodotoxin (TTX; 10µM; 2nd dotted red line). This tracing shows that BTS 
causes cessation of contraction without altering Ca2+ cycling, with the latter being 
abolished by TTX. 
Supplemental Figure 4.0.1: Raw tracings of Fluo-2 AM-




Supplemental Figure 2. Effects of 1 d of doxorubicin (DOX; 0.2 µM; gray bars) or vehicle 
(DMSO; open bars) administration, with or without electrical field stimulation (STIM; 
20V, 12 ms pulses at 1Hz for 1 h/d) on Akt phosphorylation. STIM reduced 
phosphorylation of Akt (p-Akt; T308) after 1 d (P<0.01 STIM effect). Representative gel 
images of p-Akt and total Akt expression are shown at the top of the panel for a sub-set of 
replicates. All data are mean ± SEM, with individual data points shown with each bar. *, 










Supplemental Figure 4.0.2: Effects of 1d 
doxorubicin treatment on p-Akt. 
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Supplemental Figure 3. Effects of doxorubicin (DOX; 0.2 µM) administration, with or 
without capsaicin administration (CAP; 100 nM), on mitochondrial ROS production and 
content. A) CAP administration was unable to mitigate the effects of 3 d of DOX 
administration to increase ROS production (n=6/bar; P<0.01 DOX effect) or (B) prevent 
the loss of mitochondrial content (n=10/bar; P<0.01 DOX effect). All data are mean ± 
SEM, with individual data points shown with each bar. *, P<0.05 and **, P<0.01 for DOX 

















Supplemental Figure 4. Effects of 1 hour of doxorubicin (DOX; 0.2 µM; gray bars) or 
vehicle (DMSO; open bars) administration, with or without electrical field stimulation 
(STIM; 20V, 12 ms pulses at 1Hz for 1 h/d) on AMPK phosphorylation. (A) No effect of 
DOX or STIM for 1 h was found on phosphorylation of AMPK (p-AMPK; T172). 
Representative gel images of p-AMPK and total AMPK expression are shown at the top of 
the panel for a sub-set of replicates. All data are mean ± SEM, with individual data points 
shown with each bar. 
Supplemental Figure 4 0.4: Effects of 1hr DOX 




Supplementalal Video 1 10um scale.avi
 
Supplemental Video 4.0.1:  Intracellular Ca2+ cycling in d7 myotube. 
Supplemental Video 1. Pseudocolor video of intracellular Ca2+ cycling in d7 myotube 
measured by Fluo-2 AM in response to 20V, 12 ms pulses at 1Hz. Time signatures for each 
image are provided at the bottom (frame rate=40/s, scale bar=10 µm). 
 
supplemental video 2  10um scale.avi
 
Supplemental Video 4.0.2: Contractile dynamics in d7 C2C12 myotubes. 
Supplemental Video 2. Contractile dynamics in d7 C2C12 myotubes with 2 μm latex 
beads (1:1000)  in response to 20V, 12 ms pulses at 1Hz. Time signatures provided at the 






CHAPTER 5: COMPREHENSIVE DISCUSSION 
 
Introduction 
There is a consensus that cancer-related muscle wasting might be caused by 
multiple tumor factors, host-derived factors, and cancer treatments (5). Muscle wasting is 
a primary marker for serious clinical consequences such as physical impairment, 
increased morbidity, and increased mortality. Although studies into the cause of cancer-
related muscle atrophy have spanned multiple decades, clinical trials addressing them 
individually have proven ineffective (1, 8, 9), and little is known about the mechanisms 
and effects of various cancers and their treatments on skeletal muscle. The overall aim of 
this dissertation was to identify and understand the mediators of muscle wasting in cancer 
patients and to examine the role of muscle contraction to help maintain muscle size and 
function. To address these questions we studied two different populations of cancer 
patients (lung and breast cancer) to tease out the effects of tumor-derived factors or 
chemotherapeutics to cause atrophy and used an in vitro skeletal muscle system to 
elucidate the mechanism by which muscle contraction may be beneficial. 
Regulation of skeletal muscle mass 
In the first part of this dissertation, our goal was to identify and understand the 
mediators of muscle wasting in cancer patients. We utilized an in vitro skeletal muscle 
system to examine the effects of tumor factors from patients and chemotherapies used in 
treatment to directly affect skeletal muscle mass. Our methodology involved treating 
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myotubes differentiated to the point that they showed stable myosin contact/myotube 
size, expressed myofilament proteins and arranged these into functioning sarcomeres.  Of 
note, studies in the cancer cachexia field that have examined tumor-related factors using 
myotube cultures often compare conditioned media treated cells with non-treated 
controls. We found these studies insufficiently controlled and added dilution and non-
cancer cell controls.  
When we examined murine and patient tumor conditioned media (CM) to promote 
atrophy and affect mitochondrial health on fully mature myotubes, we found no effect of 
the CM. Collectively, our results argue against the hypothesis that there is a direct effect of 
tumor derived factors to cause atrophy and/or perturb mitochondrial health. We could 
recapitulate findings from other labs that tumor-conditioned media caused reduced 
myotube myosin content, but our dilution and non-cancer cell controls suggest that these 
results are most likely related to CM inhibiting myotube growth.  
In breast cancer patients undergoing chemotherapy treatment, we observed reduced 
single muscle fiber CSA, mitochondrial content and increased oxidative stress. Cancer 
patients are often treated with chemotherapy, whose side effects are at times 
underestimated. Applying our in vitro model to test the effects of chemotherapy to directly 
affect skeletal muscle cells, we found similar phenotypes of muscle atrophy, mitochondrial 
rarefaction and increased ROS production. Moreover, diminishing mitochondrial ROS 




There are limitations of our cell culture findings in both of the aforementioned 
studies. Thus, we have outlined several future experiments to address these limitations.  
 For conditioned media experiments, the bolus treatment protocol that we used does 
not simulate conditions found in vivo, where muscle is exposed to ongoing kinetics of 
constant tumor secretion of factors that could influence muscle. This could be remedied by 
the application of a “trasnwell” co-culture model, where human tumor cells are placed in 
the same chamber as mature myotubes allowing the media to be shared between both cell 
types. The primary outcomes for this experiment would be myosin content, mitochondrial 
ROS and mitochondrial content. However, this constant and high concentration of CM may 
provide an exaggeratedly high level of tumor-related factors for muscle, similar to animal 
models, where tumors exceed 5% of their mass before cachexia is seen. Thus, while this 
type of transwell approach may better reproduce the kinetics of tumor secreted factors, it 
still suffers the problem of supraphysiological doses of those factors.  
Perhaps more importantly, CM from a monolayer of cultured tumor cells may not 
adequately reflect tumor production of secreted factors to cause the phenotype seen in 
xenograft models (2-4). That is, tumors exist in a three-dimensional environment in vivo 
and there is evidence that monolayers of cells do not reflect the behavior of solid, 3D 
tumors. Cancer organoids are cancer cells grown in a 3D system with near-physiological 
architectures that are reported to retain specific functions of the parent tumors.  Using this 
technique of growing tumor cells in vitro, lung cancer patients biopsied cells can be grown 
into organoids and the CM collected for the bolus experimental model on mature C2C12 
myotubes. This organoid system can also be applied to recapitulate drug responses of 
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tumors when treated with cisplatin (CIS), paclitaxel (TAXOL) or doxorubicin (DOX), the 
CM can be collected for treatment of mature C2C12 myotubes. The primary outcomes for 
these sets of experiments would be myotube myosin content and mitochondrial health. Use 
of organoid cultures of human tumors would provide the most clinically relevant system for 
preclinical evaluation of the effects of tumor-related factors on myotubes (12, 14). 
As previously mentioned, non-muscle host factors may contribute to muscle 
wasting in cancer patients, as skeletal muscle atrophy in pre-clinical models are often 
associated with heightened inflammatory mediators and upregulation of inflammatory 
signaling in skeletal muscle. This is also characterized by recruitment of immune cells to 
skeletal muscle. The origins of cytokines are still debated, but an alternative hypothesis in 
the field is that tumor-derived factors may contribute to muscle wasting by inciting host 
immune responses (6). Indeed, the presence of the tumor itself causes the body to produce 
an acute phase response (11), and macrophages appear to be the source of some of the 
principal mediators of cachexia, such as TNF-α or IL6 (7).  Conducting in vitro co-culture 
experiments such as described by Venter et al (13), to investigate the effects of 
stimulating macrophages with tumor conditioned media on cultured muscle could be used 
to increase our understanding of these cellular interactions The communication between 
nonmyogenic cells, such as macrophages and fibroblasts are crucial for skeletal muscle 
(13). Designing a co-culture experiment in which macrophages are in close proximity to 
mature C2C12 myotubes and treated with either standard patient CM (monolayer) or 
organoid CM may yield results that better emulate the phenotype described in patients, 
with primary outcomes of myosin content and mitochondrial health. This same 
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experiment could also be conducted with tumor cells that have been activated with 
chemotherapy, where the activated CM is used to treat the co-culture system. 
A primary outcome for many of these proposed experiments have been 
mitochondrial health. Mitochondria sustain the energy required for normal muscle 
homeostasis. However, the role of mitochondria extends beyond energy homeostasis in 
muscle. With our model, we were able to inhibit the negative effects of DOX and TAXOL 
to cause atrophy, mitochondrial ROS and mitochondrial loss, by treating the mature 
myotubes with the antioxidant compound MitoQ.  The coupling mechanisms between 
redox homeostasis, mitochondrial morphology and muscle size are still unclear. 
Mitochondria are able to change their morphology by undergoing either fusion to form 
elongated interconnected networks, or fission to generate fragmented disconnected 
mitochondria. Healthy mitochondrial dynamics are required for mitochondrial biogenesis 
via PGC-1a, for the quality-control of the organelles, and may play a role in apoptosis, 
redox homeostasis and mitochondrial dynamics. Designing experiments that identify and 
test these important mediators will be important to further elucidate how chemotherapy-
induced modifications in mitochondrial content and function contribute to muscle atrophy 
during cancer treatment. Such experiments would include treating mature myotubes with 
DOX or other oxidants looking for the activation, expression and content of 
mitochondrial morphology regulators such as Optic Atrophy 1 (Opa1, fusion) which is 
inhibited by S-nitrosylation and increased by denitrosylation, and Dynamin-1-related 
protein (Drp1, Fission) whose activity is regulated by ROS via S-nitrosylation, leading to 
increased fission. Increased mitochondrial fission has been linked with skeletal muscle 
atrophy and experiments that test for this connection may provide more insight into the 
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interplay between ROS, mitochondrial fission/loss and skeletal muscle health.  One such 
experiment would be to utilize a pharmacological inhibitor of Dpr1 such as mdivi-1 in 
cultured muscle when treated with DOX to prevent atrophy by reducing mitochondrial 
fission. The primary outcomes of these experiments would be myosin content and Drp1 
content/phosphorylation/RNA, along with mitochondrial ROS measurements. A genetic 
approach can also be used. Using the C2C12 cell line, it is possible to generate a Drp1 
knockdown (KD) model in mature myotubes. This KD model can then be tested with 
chemotherapies such as DOX, and evaluated for protection of mitochondrial health and 
further validated in an in vivo knockout model along with western blots for patients Drp1 
for confirmation of phenotype clinically. Similar experiments can be performed with the 
overexpression of PGC-1α, if mitochondrial biogenesis is important, it should prevent the 
deleterious effects of DOX and other chemotherapies 
Exercise 
We established an experimental protocol to simulate some of the exercise-induced 
changes in gene and protein expression in cultured muscle cell using myotube contraction 
via electrical stimulation (STIM).  However, three bouts of STIM on cultured cells may 
not completely reflect the complexity and time-dependent adaptation of skeletal muscle 
to exercise as in vivo. The determination of protein levels, enzymatic activity and 
functional read-outs might differ between the cells in culture and muscle in vivo. Testing 
these effects in an in vivo model may further support the results from the cell culture 
experiments. Using standard wildtype mice experiments with DOX can be performed 
with STIM on one leg, with the contralateral leg serving as a control. The outcomes for 
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these experiments would be muscle size measured by CSA, mitochondrial ROS measured 
by Amplex red assay, and mitochondrial content measured with electron microscopy. 
Secondary outcomes would include western blots for mitochondrial dynamics (Drp1, 
OPA1), antioxidant enzymes and PGC-1α content. We can further apply this in patients 
by utilizing neuromuscular electoral stimulation (NMES) with protocols informed by cell 
and animal studies, using the same metrics for primary and secondary outcomes. 
In any case, the cell culture experimental system allows the delineation of molecular 
mechanisms important for the contracting muscle fiber that cannot be performed on 
muscle in vivo. In the future, this model system will have to be adapted and refined such 
as with co-cultures, but also importantly, with validation of the mechanical stress 
stimulus we previously reported. This would be achieved by applying a cyclical 
mechanical stretch with or without DOX matching the in vitro STIM protocol of 1Hz for 
1 hour, but limiting the strain to 3.5% as reported by our studies. With this stretch system 
we can further delve into the mechanisms of the mechanical forces involved in 
maintaining muscle mass.  
Calcium signaling has been reported as an important mediator of muscle health. Our 
studies with STIM has diminished their importance in this model of mechanotransduction 
with the negative results of the transient receptor potential cation channel subfamily V 
member 1 (TrpV1) agonist capsaicin and the BTS experiments. However, stretch 
activated calcium channels have also been implicated as an important signaling aspect of 
mechanical stretch. Using pharmacological inhibitors, such as GsMTX4, of these stretch 
activated calcium channels, might help rule out their importance, by showing no 
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inhibition in the effects of STIM or stretch to prevent atrophy. Further, applying BTS 
during stretch may solidify the importance of mechanical activation of mechano sensitive 
proteins by blocking the anti-atrophic effects of stretch. 
Calcium release occurs during excitation-contraction coupling (ECC) and our data 
shows that STIM works via this system to induce contracture in cultured muscle cells. 
However, specifically targeting the main channel of calcium release in the cells has not 
been fully characterized. Ryanodine receptors (RyRs) are an important component of 
ECC that can be targeted. There are evidence that RyR agonist can be utilized to induce 
calcium and have been linked with anti-atrophic effects.  We suspect this is due to 
coupled contractures, and utilizing RyR agonist Caffeine at 4mM and 4-Chloro-m-cresol 
(4CmC) we can elucidate these mechanisms. With the IonOptix system that we have 
previously demonstrated, experiments can be performed to test the calcium and 
contracture dynamics of these agonists on C2C12 mature myotubes with and without 
DOX.  We can also apply inhibitors of ECC such as the myosin ATPase inhibitor BTS 
and the sodium channel blocker TTX as previously described, to validate the effects to 
caffeine and 4CMC to target the RyR and the importance of contracture in their 
beneficial effects. The primary outcomes for these experiments would be myotube 
myosin content and mitochondrial health with the secondary outcomes of mitochondrial 
fusion and fission dynamics. 
A common phenotype of cancer patients is muscle weakness and fatigue. Muscle 
atrophy and intrinsic weakness likely contribute to these symptoms, but the nature of 
these muscle functional deficits remain unknown. Our lab has collected data showing that 
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single muscle fibers from cancer patients are not inherently weaker than matched 
controls. Thus, impaired myofilament contractility does not appear to be the cause of 
weakness. An alternative mediator is impairments in ECC, in particular secondary to 
chemotherapy-induced ROS production. We can delve deeper into the effects of 
chemotherapy to perturb calcium responses and contracture dynamics. Overnight 
treatment with chemotherapies like DOX (0.2µM to 1µM) on mature myotubes might 
yield a reduction in response to STIM or a reduction in the fractional strain of the 
contracture. Moreover, we can then examine the importance of mitochondrial health or 
ROS to affect these calcium and contracture dynamics. Using the previously described 
MitoQ at 0.25µM, to inhibit mitochondrial ROS, during DOX treatment may prevent any 
deleterious effects of DOX to alter myotube ECC and/or contracture dynamics. Using the 
C2C12 cell line, it is possible to generate a PGC-1a knockdown (KD) model in mature 
myotubes. This KD model can then be tested with chemotherapies such as DOX, during 
electrical stimulation, and evaluated for any loss of anti-atrophic effects of exercise via 
loss of mitochondrial health and further validated in an in vivo knockout model along 
with western blots for patients Drp1and Pgc-1a for confirmation of phenotype clinically.   
The studies discussed have been designed around the murine C2C12 skeletal muscle 
cell line. This is a transformed cell line that may not fully match in vivo muscle, therefore 
conducting all these studies on primary human muscle cells may provide a clearer picture 
of the changes in patient muscle. There are commercially available Human Skeletal 
Muscle Myoblasts, which can be used as a consistent control cell line to conduct all 
experiments mentioned.  However, the most relevant option is to use primary human 
myoblasts from muscle biopsies which are a valuable resource for modeling human 
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muscle disease in vitro. Human skeletal muscle biopsies often contain extensive 
populations of non-myogenic cells, such as adipocytes and fibroblasts, adding to the 
complexity of isolating primary cells from patients. Thus, developing proper isolation 
techniques such as those published by Spinazzola et al (10) will be important before they 
can be utilized for modelling studies. Besides exercise, molecules acting as exercise 
mimetics might also be of interest in the attempt to counteract the adverse side effects of 
chemotherapeutical agents. This would most likely occur when such adverse effects are 
mostly reversible and mainly involve preventing mitochondrial impairment. 
Conclusion 
Performing clinical trials in cancer patients with muscle wasting is very 
challenging and high drop‐out rates are common. Well‐designed preclinical models still 
have a vital role to play in screening different potential myoprotective treatments and 
guiding the selection of the best candidates for more detailed clinical testing. 
Experiments using cultured myotubes are a key step in investigating the direct effects of 
catabolic agents and to determine the protective effect of anti‐muscle atrophy treatments. 
Typically, experimental outcomes employ measurements of myotube morphology (e.g., 
fiber diameter) and we have expanded this to include myosin content and the expression 
levels of anabolic and catabolic mediators in muscle. Several approaches to improve the 
modeling of muscle in an in vitro setting have been described. These have included the 
use of two or three‐dimensional systems, co-culturing techniques, and use of electrical 
stimulation. Ideally, attempts would be made to test myotube responses that combine 
several features of the in vivo milieu to study disease‐related muscle atrophy. 
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Cancer-related skeletal muscle wasting is a complex syndrome with multiple 
contributing factors and signaling pathways. Increasing our knowledge of the 
mechanisms involved in muscle wasting, and how mechanical stimulation prevents this 
will help point the way to developing treatments. This work makes important 
contributions to the field by informing the direction and design of future clinical 
interventions in the management of cancer-related muscle atrophy. In conclusion, our 
findings have uncovered previously unknown relationships that will inform clinical best 
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